

CURRICULUM VITAE

NAME: Bente Lomholt Langdahl
DOB: August 12, 1961
ORCID: 0000-0002-8712-7199

EDUCATION

2004: DMSci, Aarhus University. Thesis: *The genetics of bone mass and risk of osteoporotic fractures*
2002: Specialist Authorisation, Endocrinology
1995: PhD, Faculty of Health, Aarhus University. Thesis: *Investigations on a possible pathogenic role of thyroid hormones in postmenopausal osteoporosis.*
1988: MD, Aarhus University

CURRENT AND MOST RECENT POSITIONS

2004 - Consultant endocrinologist, Dept. of Endocrinology and Internal Medicine Aarhus University Hospital
2012 - Professor, Dept. of Clinical Medicine, Aarhus University
2015 - Honorary Clinical Senior Lecturer, University of Edinburgh, UK
2004-12: Associate Professor, Dept. of Clinical Medicine, Aarhus University

INTERNATIONAL EXCHANGE:

2016: Visiting Professor, Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, The University of Edinburgh

AWARDS AND HONOURS

2023: The Frederic C. Bartter Award, American Society for Bone and Mineral Research
2023: The Mosekilde Award, Danish Bone Society
2017: The Philippe Bordier Clinical Research Award, European Calcified Tissue Society
1997: Young Investigator Award, European Calcified Tissue Society
1995: 1. price, The Danish Internal Medicine Society

BIBLIOGRAPHIC OVERVIEW

Total peer-reviewed publications: 291 (48 as first author, 73 as last or corresponding author).

Citations: 17.936 (Scopus)

H-index: 62 (Scopus)

Field-Weighted Citation Impact: 2,13 (average 1,0) meaning that B. Langdahl has been cited twice as much as the average within her subject area (SciVal)

More than 50% (53,7%) of the publications are published in the top 10% highest ranked journals within the subject area (SciVal).

Published in high-impact journals eg. Lancet (SJR 13.103 and Lancet Diabetes and Endocrinology (SJR 8.596).

Textbook chapters: 10

SUPERVISION

Main supervisor: 20 PhD-students (15 completed and 5 ongoing), 1 biology student and 6 medical students.

TEACHING (selected)

2007- European Calcified Tissue Society: ECTS PhD training course: Scientific programme, course leader and teaching (osteoporosis, medical treatment of osteoporosis, interactive workshops on research career planning and project planning)
2005- Teaching of pregraduate medical students in endocrinology and metabolic bone diseases.
2003- Endocrinology. Postgraduate training course for specialists
1995- PhD course in bone biology. Aarhus University: Scientific programme, course leader and teaching (medical treatment of osteoporosis, osteogenesis imperfecta, rare metabolic bone diseases).

COMMISSIONS OF TRUST

2015-2023 President, Intl Federation of Musculoskeletal Research Societies (IFMRS)
2022- Member of the Nominations Committee American Society for Bone Mineral Research (ASBMR)
2021-2023 Member of the Professional Practice Committee American Society for Bone Mineral Research (ASBMR)
2010-2016 President, European Calcified Tissue Society (ECTS)
2006-2010 President, Danish Bone Society
2000-2004 Board Member, Danish Endocrine Society

1994-2000 Treasurer, Danish Bone Society, Board Member, Secretary
 1997-2011 Chair of training committee, Treasurer, European Calcified Tissue Society (ECTS)
 2009- Chair of the Data Monitoring Board concerning the ZIPP study (Zoledronate In the Prevention of Paget's) Edinburgh University:

 2016-2020 Editor-in-chief of BoneReports
 2023- Associate editor of Journal of Bone and Mineral Research
 2013- Associate editor of Bone
 2013-2021 Associate editor of European Journal of Endocrinology

 2003- Member of the editorial board of Calcified Tissue International
 2016-2024 Member of the editorial board of Osteoporosis International
 2020- Member of the editorial board of Journal of Clinical Endocrinology and Metabolism

Referee for scientific journals: Calcified Tissue International: performed 155 reviews, European Journal of Endocrinology: performed 52 reviews, Osteoporosis International: performed 75 reviews, Bone: performed 68 reviews, Journal of Bone and Mineral Research: performed > 30 reviews, Journal of Clinical Endocrinology and Metabolism: performed > 30 reviews, Scandinavian journal of Rheumatology: performed > 20 reviews.

Member of evaluation committees for 4 doctoral theses (DMSc) and 10 international and 21 Danish PhD theses 2002-2024.

Referee duties for research applications at an international level.

2015-21 Co-chair of the ASBMR Rising Star Award Committee. Every year I oversee the review process of 20-30 applications, international as well as US based, for this award and chair the committee meeting that identifies the recipients of the awards.
 2005-13 Reviewed several applications every year for the different grants and awards provided by ECTS: ECTS PhD Studentship, ECTS Postdoctoral Fellowship, ECTS carrier establishment award, ECTS/Amgen Bone Biology Fellowship, ECTS/Servier Fellowship, ECTS Iain Boyle Award, ECTS Philippe Bordier Clinical Award
 2012- Reviewer for US-Israel Binational Science Foundation.
 2012- Reviewer for the Health Research Council of New Zealand.

Referee duties for research applications at a national level.

2009- The Research Foundation for the Region of Southern Denmark. I review applications annually.

INVITED PRESENTATIONS

In total 19 presentations. American Society for Bone and Mineral Research (2017, 2020, 2022, 2024), European Calcified Tissue Society (2017, 2019, 2022), European Endocrine Society (2018, 2023), Endocrine Society (2018, 2021), Australian and New Zealand Bone and Mineral Society (2018), International Congress of Endocrinology (2017 and 2021)

LEADERSHIP OF RESEARCH COLLABORATIONS

I have more than 25 years of experience in clinical and basic research within the field of osteoporosis and metabolic bone diseases and have been heading my own research group since 2004. I am collaborating with researchers at the Institute of Anatomy, AU on preclinical models, with Institute of iNANO, AU on advanced imaging on bone specimens, with the department of cardiology, AUH on cardiac CT and opportunistic screening for osteoporosis, and with the department of pathology, AUH on bone histomorphometry. I have also established collaboration with professor Moustapha Kassem, KMEB on in vitro studies, with professor Niklas Jørgensen, Rigshospitalet on biochemical markers of bone turnover, and with many Danish clinical colleagues on clinical trials. I have also developed strong international collaborations starting in 1995 with projects on genetics of osteoporosis. Since then, I have twice been the coordinating investigator on HORIZON 2020 applications including investigators from 8 different European countries.
 In addition, I have more than 20 years of experience as a consultant and leader of clinical services at Aarhus University Hospital.

RESEARCH FUNDING (recent 5 years)

2022	Novo Nordisk Foundation	Co-applicant	DKR 10,000,000
	Early life determinants of skeletal maturation and endocrine health in young adults – A nationwide birth cohort study		
2021	Novo Nordisk Foundation	Main Applicant	DKR 25,000,000

	Optimised Long-term Management of Osteoporosis – the OPTIMISE project		
2020	Novo Nordisk Foundation	Co-applicant	DKR 10,000,000
	Safety and Efficacy of Alendronate for Osteoporosis with Nephropathy (SEAL-ON): A randomised double-blinded placebo-controlled trial		
2017	Novo Nordisk Foundation	Main Applicant	DKR 1,025,000
	Treatment with Zoledronate subsequent to Denosumab in Osteoporosis – the ZOLARMAB project		
2017	Amgen	Main Applicant	DKR 2,400,000
	Treatment with Zoledronate subsequent to Denosumab in Osteoporosis – the ZOLARMAB project		
2017	Novo Nordisk	Main Applicant	DKR 1,800,000
	The effect of Liraglutide on Bone mass and Bone Turnover		
2016	P Carl Petersens Fond	Main Applicant	DKR 600,000
	The predictive value of bone turnover markers during discontinuation of alendronate: the PROSA study		

Total number of publications: 298, H-index: 62 (scopus)

First author: 48 publications, Corresponding/Last author: 75 publications

1. Bader-Larsen K, Nielsen BU, Henriksen E, Bryrup T, Ileo-Hansen C, Mathiesen IHM, Faruholt-Jepsen D, Qvist T, Oturai P, **Langdahl B**, Jeppesen M, Olsen HV, Pressler T, Skov M, Olsen MF, Transform CF Study Group. Body mass, linear growth, and body composition before and after the introduction of elexacaftor/tezacaftor/ivacaftor among children and adults with cystic fibrosis. Clin Nutr 2025 Epub.
2. Yildiz BO, Armeni E, Balodimou C, Biondi B, Ciudin A, Frühbeck G, Fuleihan GE, Geer EB, Gillard P, Gordon CM, Goulis D, Hammer GD, Höybye D, **Langdahl BL**, Laufer AB, vander Lely AJ, Macut D, Mader JK, McGowan B, Novac E, Pignatelli D, Pfeifer M, Radic L, Shah V, Stratakis CA, Treiber G, Vrachnis DN, Wilding J, Yazici D, Celik O. EndoBridge 2024: pearls and highlights. Hormones 2025 Epub.
3. Linde KN, Rytter S, **Langdahl BL**, Madsen F, Stilling M. Migration of cementless total knee arthroplasty is mitigated by both local intraoperative zoledronate and postoperative denosumab: a randomized controlled trial. Bone Joint J 2025 107-B(8):793-803.
4. Hadji P, Aapro M, Al-Dagri N, Alokail M, Biver E, Body JJ, Brandi ML, Brown J, Confavreux C, Cortet B, Drake M, Ebeling P, Eriksen EF, Fuleihan GE, Guise TA, Harvey NC, Kurth A, **Langdahl B**, Lems W, Matijevic R, McCloskey E, Nappi R, Palacios S, Pfeiler G, Reginster JY, Rizzoli R, Santini D, Tuzun S, Poznak DV, Villiers T, Zillikens MC, Coleman R. Management of aromatase inhibitor-associated bone loss (AIBL) in women with hormone-sensitive breast cancer: an updated joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG. J Bone Oncol 2025 53:100694
5. Sølling AS, Laursen NA, Harsløf T, **Langdahl BL**. Antiresorptive therapy for osteoporosis in older subjects. Gerontology 2025 71(4):297-304
6. Ali DS, Khan AA, Morrison A, Tetradis S, Mirza RD, El Rabbany M, Abrahamsen B, Aghaloo TL, Al-Alwani H, AL-Dabagh R, Anastasilakis Ad, Bhandari M, Body JJ, Brandi M, Brignardello-Petersen R, Brown JP, Cheung AM, Compston J, Cooper C, Diez-Perez A, Ferrair SL, Guyatt G, Hanley D, Harvey NC, Josse RG, Kendler DL, Khan S, Kim S, **Langdahl BL**, Magopoulos C, Masri BK, Morgan SL, Morin SN, Napoli N, Obermayer-Pietsch B, Palermo A, Pepe J, Peters E, Pierroz DD, Rizzoli R, Saunders DP, Stanford CM, Sulimani R, Taguchi A, Tanaka S, Watts NB, Samudio J, Zillikens MC, Ruggiero SL. Antiresorptive therapy to reduce fracture risk and effects on dental implant outcomes in patients with osteoporosis: A systematic review and osteonecrosis of the jaw taskforce consensus statement. Endocr Pract 2025 31(5):686-698.
7. Björnsdóttir S, Kamal W, Mannstadt M, Mäkitie O, Spelman T, Kämpe O, **Langdahl BL**. Increased risk of vertebral fractures and reduced risk of femur fractures in patients with chronic hypoparathyroidism: a nationwide cohort study in Sweden. J Bone Miner Res 2025 40(7):860-67.
8. Skipper MT, Birkebæk N, Jensen RB, **Langdahl BL**, Tuckuviene R, Wehner PS, Schmiegelow K, Frandsen TL, Andrés-Jensen L, Albertsen BK. Risk of metabolic syndrome and glucose homeostasis among childhood and young adult lymphoblastic leukemia survivors: Part of the ALL-STAR study. Pediatr Blood Cancer 2025 Epub.
9. Rosendahl SB, Starup-Linde J, Storgaard M, **Langdahl B**. Investigations of osteoporosis in persons living with human immunodeficiency virus: The HOST study. Calcif Tissue Int. 2025 116(1):64.
10. Sopina L, Hitz MF, Thygesen LC, **Langdahl B**, Ladefoged BT, Kruse M. Healthcare and productivity cost of osteoporosis: a Danish register-based quasi-experimental study. Osteoporos Int 2025 Epub.
11. Starup-Linde J, Støy J, Grinderslev PB, **Langdahl B**, Harsløf T. Prevalence and risk factors for osteoporosis in type 1 diabetes – results from an observational study. Osteoporos Int 2025 Epub.
12. Ferrari S, Betah D, Feldman RG, **Langdahl BL**, Oates M, Timoshanko J, Wang Z, Dhaliwal R. Romosozumab improves tissue thickness-adjusted trabecular bone score in women with osteoporosis and diabetes. J Clin Endocrinol Metab 2025 dgae862.

13. Lewiecki EM, Bilezikian JP, Clark A, Collins MT, Kado DM, Lane J, **Langdahl B**, McClung MR, Snyder JP, Stein EM. Proceedings of the 2024 Santa Fe Bone Symposium: Update on the management of osteoporosis and rare bone diseases. *J Clin Densitom* 2025 28(1):101559.
14. Laursen N, Sølling AS, Harsløf T, **Langdahl B**. Clinical experience with denosumab discontinuation. *Osteoporos Int* 2025 Epub.
15. Chung US, **Langdahl B**, Plebanski R, Czerwinski E, Dokoupilova E, Supronik J, Rosa J, Mydlak A, Sapula R, Rowinska-Osuch A, Baek HK, Urboniene A, Mordaka R, Ahn S, Rho YH, Ban J, Eastell R. SB16 versus reference denosumab in postmenopausal women with osteoporosis: 18-month outcomes of a phase III randomized clinical trial. *Bone* 2024 Epub.
16. Folkestad L, Prakash SK, Nagamani SCS, Andersen NH, Carter E, Hald JD, Johnson RJ, **Langdahl B**, Perfetto EM, Raggio C, Ralston S, Sandhaus RA, Semler O, Orwoll E. Cardiovascular disease in adults with osteogenesis imperfecta: Clinical characteristics, care recommendations and research priorities identified using a modified Delphi technique. *J Bone Miner Res* 2024 Epub.
17. Therkildsen J, Klose-Jensen R, Hänel M, **Langdahl BL**, Thomsen JS, Manske SL, Keller KK, Hauge EM. Detecting new erosions in rheumatoid arthritis over one year – Radiography and high-resolution computed tomography of finger joints. *Joint Bone Spine* 2024 92(1):105812.
18. Hald JD, Hald AW, Harsløf T, **Langdahl B**, Bruun JM. Treatment with bariatric surgery in patients with osteogenesis imperfecta and severe obesity. *Bone Rep* 2024 23:101811.
19. Mäkinen VN, Sølling AS, McClung M, **Langdahl BL**. Romosozumab for the treatment of osteoporosis – a systematic review. *J Endocrinol Invest* 2024 Epub.
20. **Langdahl B**, Chung YS, Plebansk R, Czerwinski E, Dokoupilova E, Supronik J, Rosa J, Mydlak A, Rowinska-Osuch A, Baek KH, Urboniene A, Mordaka R, Ahn S, Rho YH, Ban J, Eastell R. Proposed denosumab biosimilar SB16 vs reference denosumab in postmenopausal osteoporosis: Phase 3 results up to month 12. *J Clin Endocrinol Metab* 2024 Epub.
21. Glorieux FH, **Langdahl B**, Charpurlat R, De Beur SJ, Sutton VR, Poole KES, Dahir KM, Orwoll ES, Willie BM, Mikolajewicz N, Zimmermann E, Hosseinitabatabaei S, Ominsky MS, Saville C, Clancy J, MacKinnon A, Mistry A, Javaid MK. Setrusumab for the treatment of osteogenesis imperfecta: 12-month results from the phase 2b Asteroid study. *J Bone Miner Res* 2024 39(9):1215-28.
22. Cosman F, Lewiecki EM, Eastell R, Ebeling PR, De Beur SJ, **Langdahl B**, Rhee Y, Fuleihan GE, Kiel DP, Schousboe JT, Borges JL, Cheung AM, Diez-Perez A, Hadji P, Tanaka S, Thomasius F, Xia W, Cummings SR. Goal-directed osteoporosis treatment: ASBMR/BHOF task force position statement 2024. *J Bone Miner Res* 2024 39(10) 1393-1405.
23. Hartz MC, Johannessen FB, Harsløf T, **Langdahl BL**: The Effectiveness and Safety of Romosozumab and Teriparatide in Postmenopausal women with Osteoporosis. *J Clin Endocrinol Metab* 2024 Epub.
24. Rud CL, Hvistendahl MK, **Langdahl BL**, Kraglund F, Baunwall SMD, Lal S, Jeppesen PB, Hvas CL. Protein-based oral rehydration solutions for patients with an ileostomy: A randomized, double-blinded crossover study. *Clin Nutr* 2024 43(7):1747-58.
25. Hald JD, **Langdahl B**, Folkestad L, Wekre LL, Johnson R, Nagamani SCS, Raggio C, Ralston SH, Semler O, Tosi L, Orwoll E. Osteogenesis Imperfecta: Skeletal and non-skeletal challenges in adulthood. *Calcif Tissue Int* 2024 Epub.
26. Therkildsen J, Klose-Jensen R, Hänel M, **Langdahl BL**, Thygesen J, Thomsen JS, Manske SL, Keller KK, Hauge EM. Erosive Progression by high-resolution peripheral quantitative computed tomography and conventional radiography in rheumatoid arthritis. *Reumatology* 2024 Epub.
27. Rubæk M, Broholm-Jørgensen M, Andersen S, Jakobsen PR, Rothmann MJ, **Langdahl B**, Hitz MF, Holmberg T. Development of a program theory for osteoporosis patient education in Denmark: A qualitative study based on realist evaluation. *BMC Geriatrics* 24(1):346.
28. Lane J, **Langdahl B**, Stone M, Kurth A, Oates M, Timoshanko J, Wang Z, Libanati C, Cosman F. Romosozumab in patients who experienced an on-study fracture: post hoc analyses of the FRAME and ARCH phase 3 trials. *Osteoporos Int* 2024 35(7):1175-1204.
29. Starup-Linde J, Bardenfleth H, Harsløf T, **Langdahl B**. Racial differences as an explanation for observed differences in bone tissue stiffness, hardness, and bone turnover markers. *J Bone Miner Res* 2024 39(11) 1688-89.
30. Foessel I, Ackert-Bicknell CL, Kague E, Laskou F, Jakob F, Karasik D, Obermayer-Pietsch B, Alonso N, Bjørnerem A, Brandi ML, Busse B, Calado A, Cebi AH, Christou M, Curran KM, Hald JD, Semeraro MD, Douni E, Duncan EL, Duran I, Formosa MM, Gabet Y, Ghatan S, Gkitakou A, Hassler EM, Höglér W, Heino TJ, Hendrickx G, Khashayer P, Kiel DP, Koromani F, **Langdahl B**, Lopes P, Mäkitie O, Maurizi A, Medina-Gomez C, Ntzani E, Ohlsson C, Prijatelj V, Rabionet R, Reppe S, Rivadeneira F, Roshchupkin G, Sharma N, Sør Kn Styrkarsdóttir U, Szulc P, Teti A, Tobias J, Valjevac A, van de Peppel J, van der Eerden B, van Rietbergen B, Zekic T, Zillikens MC. A perspective on muscle phenotyping in musculoskeletal research. *Trends Endocrinol Metab* 2024 35(6):478-89.
31. Cosman F, **Langdahl BL**, Leder BZ. Treatment sequence for osteoporosis. *Endocr Pract* 2024 30(5):490-96.
32. Cheneymann A, Therkildsen J, Winther S, Nissen L, Thygesen J, **Langdahl BL**, Hauge EM, Böttcher M. Bone mineral density derived from cardiac CT scans: Using contrast enhanced scans for opportunistic screening. *J Clin Densitom* 2023 27(1):101441.

33. Hald JD, Keerie C, Weir CJ, Javaid MK, Lam W, Osborne P, Walsh J, **Langdahl BL**, Ralston SH. Protocol of a randomised trial of teriparatide followed by zoledronic acid to reduce fracture risk in adults with osteogenesis imperfecta. *BMD Open* 2023 13(11):e078164.
34. Hikmet R, Harsløf T, **Langdahl BL**. The effect of effervescent and buffered alendronate compared to conventional alendronate on markers of bone turnover: A randomised non-inferiority trial. *Calcif Tissue Int* 2023 113(5):532-9.
35. Harsløf T, Hikmet R, Ebbelhøj E, **Langdahl B**. Bone turnover decreases and bone structure improves during treatment with weekly high-dose methylprednisolone for 12 weeks in Graves' orbitopathy. *Endocrine* 2023 82(3):664-72.
36. Therkildsen J, Rohde PD, Nissen L, Thygesen J, Hauge EM, **Langdahl BL**, Boettcher M, Nyegaard M, Winther S. A genome-wide genomic score added to standard recommendation stratification tools does not improve the identification of patients with very low bone mineral density. *Osteoporosis Int* 2023 34(11):1893-1906.
37. Folkestad L, Hald JD, Tosi L, Raggio C, Semler O, **Langdahl B**, Ralston SH. Osteogenesis Imperfecta is more than a pediatric disorder – there is a need for adult care evidence to guide clinicians. *J Clin Endocrinol Metab* 2024 190(2):e866-67.
38. Meinhardsson JM, Klose-Jensen R, Therkildsen J, **Langdahl B**, Hauge EM, Keller KK. High-resolution peripheral quantitative computed tomography for the evaluation of bone erosions of metatarsophalangeal joints in patients with rheumatoid arthritis. *Int J Rheum Dis* 2023 Epub.
39. Starup-Linde J, Hygum K, **Langdahl B**. Effect of incretins on skeletal health. *Curr Opin Endocrinol Diabetes Obes* 2023 30(4):206-212.
40. Granild-Jensen JB, Møller-Madsen B, Raskauskaite G, Farholt S, Søndergaard C, Sørensen TH, Vestergaard ET, **Langdahl BL**. Zoledronate increases bone mineral density in non-ambulant children with cerebral palsy: A randomized controlled trial. *J Clin Endocrinol Metab* 2023 108(11):2840-51.
41. Händel MN, Cardoso I, von Bülow C, Rohde JF, Ussing A, Nielsen SM, Christensen R, Body JJ, Brandi ML, Diez-Perez A, Hadji P, Javaid MK, Lems WF, Nogues X, Roux C, Minisola S, Kurth A, Thomas T, Prieto-Alhambra D, Ferrari SL, **Langdahl B**, Abramhansen B. Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials. *BMJ* 2023 381:e068033.
42. Ferrari S, **Langdahl B**. Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone. *Nat Rev Rheumatol* 2023 19(5) 307-17.
43. Alonso N, Albagha OME, Azfer A, Larraz-Prieto B, Berg K, Riches PL, Ostanek B, Kocjan T, Marc J, **Langdahl BL**, Ralston SH. Genome-wide association study identifies genetic variants which predict the response of bone mineral density to teriparatide therapy. *Ann Rheum Dis* 2023 82(7) 985-91.
44. Huang CF, Chen JF, Reid IR, Chan WP, Ebeling PR, **Langdahl B**, Tu ST, Matsumoto T, Chan DC, Chung YS, Chen FP, Lewiecki EM, Tsai KS, Yang RS, Ang SB, Huang KE, Chang YF, Chen CH, Lee JK, Ma HI, Xia W, Mithal A, Kendler DL, Cooper C, Hwang JS, Wu CH. Asia-Pacific consensus on osteoporotic fracture prevention in postmenopausal women with low bone mass or osteoporosis but no fragility fractures. *J Formos Med Assoc* 2023 Epub.
45. Hald JD, Beck-Nielsen S, Gregersen PA, Gjørup H, **Langdahl B**. Pycnodysostosis in children and adults. *Bone* 2023 169:116674.
46. Granild-Jensen JB, Pedersen LK, **Langdahl B**, Starup-Linde J, Rackauskaite G, Farholt S, Søndergaard C, Vestergaard ET, Møller-Madsen B. Cerebral palsy and bisphosphonates – and what can be learned from other types of secondary osteoporosis in children: A scoping review. *Acta Paediatr* 2023 112(4) 617-29.
47. Pedersen AB, Nørholt SE, Rejnmark L, **Langdahl B**, Starch-Jensen T, Sørensen HT. Genome-wide association study of osteonecrosis of the jaw in Danish patients receiving antiresorptive therapy for osteoporosis: A case-control study. *Bone Rep* 2022 18:101648.
48. Sølling AS, Tsourdi E, Harsløf T, **Langdahl BL**. Denosumab discontinuation. *Curr Osteoporosis Rep* 2023 21(1) 95-103.
49. Sølling AS, Harsløf T, Jørgensen NR, **Langdahl B**. Changes in RANKL and TRAcP 5b after discontinuation of denosumab suggest RANKL mediated formation of osteoclasts results in the increased bone resorption. *Osteoporos Int* 2023 34(3) 599-605.
50. Levy-Schousboe K, Marchmann P, Frimodt-Møller M, Peters CD, Kjærgaard KD, Jensen JD, Strandhave C, Sandstrøm H, Hitz MF, **Langdahl B**, Vestergaard P, Brasen CL, Schmedes A, Madsen JS, Jørgensen NR, Frøkjær JB, Frandsen NE, Petersen I, Hansen D. Vitamin K supplementation and bone mineral density in dialysis: Results of the double-blind, randomized, placebo-controlled RenaKvit trial. *Nephrol Dial Transplant* 2023 38(10):2131-42.
51. Granild-Jensen JB, Pedersen AB, Kristiansen EB, **Langdahl B**, Møller-Madsen B, Søndergaard C, Farholt S, Vestergaard ET, Rackauskaite G. Fracture rates in children with cerebral palsy: A Danish, nationwide register-based study. *Clin Epidemiol* 2022 14:1405-14.
52. Sølling AS, Harsløf T, Brockstedt HK, **Langdahl B**. Discontinuation of denosumab in men with prostate cancer. *Osteoporos Int* 2022 34(2) 291-97.

53. Murray S, **Langdahl B**, Casado E, Brooks K, Libanati C, Di Lecce L, Lazure P. Preparing the leaders of tomorrow: Leanings from a two-year community of practice in fragility fractures. *J Eur CME* 2022 11(1):2142405.
54. **Langdahl BL**, Uitterlinden AG, Ralston SH. Where is bone science taking us? *Best Pract Res Clin Rheumatol* 2022 36(3):101791.
55. **Langdahl B**, Hofbauer LC, Ferrari S, Wang Z, Fahrleitner-Pammer A, Geilen E, Lakatos P, Czerwinski E, Gimeno EJ, Timoshanko J, Oates M, Libanati C. Romosozumab efficacy and safety in European patients enrolled in the FRAME trial. *Osteoporos Int* 2022 33(12) 2527-36.
56. Björnsdóttir S, Clarke BL, Mannstadt M, **Langdahl BL**. Male osteoporosis – what are the causes, diagnostic challenges, and management. *Best Pract Res Clin Rheumatol* 2022: 101766.
57. Vrist MH, Østergaard AMH, Langaa SS, Mose FH, Fynbo CA, Theil J, **Langdahl BL**, Lauridsen TG, Bech JN: Bone turnover, mineralization, and volume estimated by ¹⁸F-sodium fluoride PET/C and biomarkers in chronic kidney disease: Mineral and bone disorder compared with bone biopsy. *Am J Nephrol* 2022 53(6):490-502.
58. Miller PD, Adachi JD, Albergaria BH, Cheung AM, Chines AA, Gielen E, **Langdahl BL**, Miyauchi A, Oates M, Reid IR, Ruiz Santiago N, Vanderkelen M, Wang Z, Yu Z. Efficacy and safety of romosozumab among postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease. *J Bone Miner Res* 2022 37(8):1437-45.
59. Starup-Linde J, Ornstrup MJ, Kjær TN, Lykkeboe S, Handberg A, Gregersen S, Harsløf T, Pedersen SB, Vestergaard P, **Langdahl BL**. Bone density and structure in overweight men with and without diabetes. *Front Endocrinol* 2022 10;13:837084
60. Cosman F, Kendler DL, **Langdahl BL**, Leder BZ, Lewiecki EM, Miyauchi A, Rojeski M, McDermott M, Oates MK, Milmont CE, Libanati C, Ferrari S. Romosozumab and antiresorptive treatment: the importance of treatment sequence. *Osteoporosis Int* 2022 33(6):1243-56.
61. Linde KN, Rytter S, Søballe K, Madsen F, **Langdahl B**, Stilling M. Component migration, bone mineral density changes, and bone turnover markers in cementless and cemented total knee arthroplasty: a prospective randomized RSA study in 53 patients with 2-year follow-up. *Knee Surg Sports Traumatol Arthrosc* 2022 30(9) 3100-13.
62. Starup-Linde J, **Langdahl B**, Vestergaard P, Harsløf T. Incident peptic ulcers and concomitant treatment of direct oral anticoagulants and oral bisphosphonates – a real-world cohort study. *Osteoporos Int* 2022 33(6) 1323-34.
63. **Langdahl BL**. Bone remodeling and modeling: Therapeutic targets for the treatment of osteoporosis. In *Osteoporotic fracture and systemic skeletal disorders*. Eds Takahashi HE, Burr DB, Yamamoto N. Springer 2021. pp. 111-128.
64. Foessel I, Bassett JHD, Bjørnerem Å, Busse B, Calada A, Chavassieux P, Christou M, Douni E, Fiedler IAK, Fonseca JE, Hassler E, Högl W, Kague E, Karasik D, Khashayar P, **Langdahl BL**, Leitch VD, Lopes P, Markozannes G, McGuigan FEA, Medina-Gomez C, Ntzani E, Oei L, Ohlsson C, Szulc P, Tobias JH, Trajanoska K, Tuzun S, Valjevac A, van Rietbergen B, Williams GR, Zekic T, Rivadeneira F, Obermayer-Pietsch B. Bone phenotyping approaches in human, mice and zebrafish – expert overview of the EU Cost Action GEMSTONE (GEnomics of MusculoSkeletal traits TranslatiOnal NEtwork). *Front Endocrinol* 2021 12:720728.
65. Wittig NK, Østergaard M, Palle J, Christensen TEK, Langdahl BL, Rejnmark L, Hauge EM, Brüel A, Thomsen JS, Birkedal H. Opportunities for biomineralization research using multiscale computed X-ray tomography as exemplified by bone imaging. *J Struct Biol* 2021 214(1): 107822.
66. Herath M, **Langdahl B**, Ebeling PR, Milat F. Challenges in the diagnosis and management of glucocorticoid-induced osteoporosis in younger and older adults. *Clin Endocrinol (Oxf)* 2021 Epub
67. Andersen JD, Folkestad L, Hald JD, Harsløf T, **Langdahl BL**, Abrahamsen B. Osteoarthritis in osteogenesis imperfecta: A nationwide register-based cohort study. *Bone* 2021 154:116222.
68. Geusens P, Feldman R, Oates M, Thomas T, Makras P, Jakob F, **Langdahl B**, Wang Z, Rojeski M, Libanati C. Romosozumab reduces incidence of new vertebral fractures across severity grades among postmenopausal women with osteoporosis. *Bone* 2021 154: 116209.
69. Bolung ACS, **Langdahl B**, Laurberg TB, Hellfritzsch MB, Gjørup H, Møller-Madsen B, Nielsen TØ, Farholt S, Gregersen PA. B3GAT3-related linkeropathy and an in-frame homozygous deletion in an adult patient. *Eur J Med Genet* 2021 64(12): 104342.
70. Klose-Jensen R, Keller KK, **Langdahl B**, Hauge EM. Acceptance and image quality of high-resolution peripheral quantitative computed tomography of the metacarpophalangeal joints in rheumatoid arthritis. *Int J Rheum Dis* 2021 24(21) 1473-81.
71. Valentin G, Ravn MB, Jensen EK, Friis K, Bhimjiyana A, Ben-Shlomo Y, Hartley A, Nielsen CP, **Langdahl B**, Gregson CL. Socio-economic inequalities in fragility fracture incidence: a systematic review and meta-analysis of 61 observational studies. *Osteoporos Int* 2021 32(12) 2433-48.
72. McClung MR, Bolognese MA, Brown JP, Reginster J-Y, Langdahl BL, Shi Yifei, Timoshanko J, Libanati C, Chines A, Oates MK. Skeletal responses to romosozumab after 12 months of denosumab. *JBM Rplus* 2021 5(7): e10512.
73. Klose-Jensen R, Therkildsen J, Blavnsfeldt AG, **Langdahl BL**, Zejden A, Thygesen J, Keller KK, Hauge EM. Diagnostic accuracy of high-resolution peripheral quantitative computed tomography and X-ray for classifying erosive rheumatoid arthritis. *Rheumatology* 2022 61(3) 963-73.

74. Sølling AS, Harsløf T, **Langdahl B**. Treatment with zoledronate subsequent to denosumab in osteoporosis: a 2-year randomized study. *J Bone Min Res* 2021 36(7):1245-54.
75. Starup-Linde JK, Viggers R, **Langdahl B**, Gregersen S, Lykkeboe S, Handberg A, Vestergaard P. Associations of circulating osteoglycin with bone parameters and metabolic markers in patients with diabetes. *Front Endocrinol* 2021 15;12:649718.
76. **Langdahl BL**, Hofbauer LC, Forfar JC. Cardiovascular safety and sclerostin inhibition – a mini-review. *J Clin Endocrinol Metab* 2021 106(7) 1845-53.
77. Rønn SH, Harsløf T, Pedersen SB, **Langdahl BL**. Vitamin K2 (menaquinone-7) increases plasma adiponectin but does not affect insulin sensitivity in postmenopausal women: a randomized controlled trial. *Eur J Clin Nutr* 2021 75(11) 1661-67.
78. Saag K, Cosman F, De Villiers T, **Langdahl B**, Scott BB, Denker AE, Pong A, Santora AC. Early changes in bone turnover and bone mineral density after discontinuation of long-term oral bisphosphonates: a post hoc analysis. *Osteoporos Int* 2021 32(9) 1879-1888.
79. Sølling AS, Harsløf T, Bruun NH, **Langdahl B**. The predictive value of bone turnover markers during discontinuation of alendronate: the PROSA study. *Osteoporos Int* 2021 32(8) 1557-66.
80. Doherty MA, **Langdahl BL**, Vogel I, Haagerup A. Clinical and genetic evaluation of Danish patients with pycnodysostosis. *Eur J Med Genet* 2021 64(9):104135.
81. Sølling AS, Christensen DH, Darvalics B, Harsløf T, Thomsen RW, **Langdahl B**. Fracture rates in patients discontinuing alendronate treatment in real life: a population-based cohort study. *Osteoporos Int* 2021 32(6) 1103-15.
82. Starup-Linde J, **Langdahl B**, Harsløf T. Does FRAX estimate fracture risk in patients with type 1 diabetes? *Bone* 2021 143:115753.
83. Binkley N, Orwoll E, Charpurlat R, **Langdahl BL**, Scott BB, Giezek H, Santora AC. Randomized, controlled trial to assess the safety and efficacy of odanacatib in the treatment of men with osteoporosis. *Osteoporosis Int* 2021 32(1) 173-184.
84. Blavnsfeldt AG, Klose-Jensen R, Thygesen J, Therkildsen P, **Langdahl BL**, Keller KK, Hauge EM. Effect of radiographic disease severity in high-resolution quantitative computed tomography assessment of metacarpophalangeal joint erosion and cysts. *Int J Rheum Dis* 2021 24(1) 112-119.
85. Al-Mashhadi Z, Viggers R, Fuglsang-Nielsen R, deVries F, van den Bergh JP, Harsløf T, **Langdahl B**, Gregersen S, Starup-Linde J. Glucose-lowering drugs and fracture risk – a systematic review. *Curr Osteoporos Rep* 2020 18(6) 737-58.
86. Tsourdi E, Zillikens MC, Meier C, Body JJ, Rodriguez EG, Anastasilakis AD, Abrahamsen B, McCloskey E, Hofbauer LC, Guanabens N, Obermayer-Pietsch B, Ralston SH, Eastell R, Pepe J, Palermo A, **Langdahl B**. Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. *J Clin Endocrinol Metab* 2020 dgaa756.
87. Rønn SH, Harsløf T, Oei L, Pedersen SB, **Langdahl BL**. The effect of vitamin MK-7 on bone mineral density and microarchitecture in postmenopausal women with osteopenia, a 3-year randomized, placebo-controlled trial. *Osteoporos Int* 2021 32(1) 185-91.
88. **Langdahl B**. Treatment of premenopausal women with osteoporosis. *J Clin Endocrinol Metab* 2020 105(12) dgaa678.
89. Fuglsang-Nielsen R, Rakvaag E, **Langdahl B**, Knudsen KEB, Hartmann B, Holst JJ, Hermansen K, Gregersen S. Effects of whey protein and dietary fiber intake on insulin sensitivity, body composition, energy expenditure, blood pressure, and appetite in subjects with abdominal obesity. *Eur J Clin Nutr* 2020 75(4) 611-19.
90. Valentin G, Friis K, Nielsen CP, Larsen FB, **Langdahl BL**. Fragility fractures and health-related quality of life: does socio-economic status widen the gap? A population-based study. *Osteoporos Int* 2020 32(1) 63-73
91. Therkildsen J, Nissen L, Jørgensen HS, Thygesen J, Ivarsen P, Frost L, Isaksen C, **Langdahl BL**, Hauge EM, Boettcher M, Winther S. Thoracic bone mineral density derived from cardiac CT is associated with greater fracture rate. *Radiology* 2020 296(3) 499-508.
92. McClung MR, Bolognese MA, Brown JP, Reginster JY, **Langdahl BL**, Maddox J, Shi Y, Rojeski M, Meisner PD, Grauer A. A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab. *Osteoporos Int* 2020 31(11) 2231-41.
93. **Langdahl B**. Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: Combined and sequential approaches. *Bone* 2020 139:115516
94. Kumarathas I, Harsløf T, Andersen CU, **Langdahl B**, Hilberg O, Bjermer L, Løkke A. The risk of osteoporosis in patients with asthma. *Eur Clin Respir J* 2020 7(1) 1763612.
95. Sølling AS, Harsløf T, **Langdahl B**. Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial. *J Bone Miner Res* 2020 35(10) 1858-70.
96. Pepe J, Body JJ, Hadji P, McCloskey E, Meier C, Obermayer-Pietsch B, Palermo A, Tsourdi E, Zillikens MC, **Langdahl B**, Ferrari S. Osteoporosis in premenopausal women: A clinical narrative review by the ECTS and IOF. *J Clin Endocrinol Metab* 2020 105(8) dgaa306
97. Recker R, Dempster D, **Langdahl B**, Giezek H, Clark S, Ellis G, de Villiers T, Valter I, Zerbini CAF, Cohn D, Santora A, Duong LT. Effects of Odanacatib on Bone Structure and Quality in Postmenopausal Women with Osteoporosis: 5-year data from the Phase 3 Long-Term Odanacatib Fracture Trial (LOFT) and its extension. *J Bone Miner Res* 2020 35(7) 1289-99

98. **Langdahl BL.** Overview of treatment approaches to osteoporosis. *Br J Pharmacol* 2020 Epub
99. Hygum K, Harsløf T, Jørgensen NR, Rungby J, Pedersen SB, **Langdahl BL.** Bone resorption is unchanged by liraglutide in type 2 diabetes patients: A randomized controlled trial. *Bone* 2020 132:115197
100. van de Laarschot DM, McKenna MJ, Abrahamsen B, **Langdahl B,** Cohen-Solal M, Guanabens N, Eastell R, Ralston SR, Zillikens MC. Medical management of patients after atypical femur fractures: a systematic review and recommendations from ECTS. *J Clin Endocrinol Metab* 2020 105(5) 1682-99
101. Starup-Linde J, Hygum K, Harsløf T, **Langdahl B.** Type1 diabetes and bone fragility: Links and risks. *Diabetes Metab Syndr Obes* 2019 12:2539-2547.
102. Starup-Linde J, Rosendahl SB, Storgaard M, **Langdahl B.** Management of osteoporosis in patients living with HIV – A systematic review and meta-analysis. *J Acquir Immune Defic Syndr* 2020 83(1) 1-8.
103. McClung MR, O'Donoghue ML, Papapoulos SE, Bone H, **Langdahl B,** Saag KG, Reid IR, Kiel DP, Cavallari I, Bonaca MP, Wiviott SD, de Villiers T, Ling X, Lippuner K, Nakamura T, Reginster JY, Rodriguez-Portales JA, Roux C, Zanchetta J, Zerbinì CAF, Park JG, Im K, Cange A, Grip LT, Heyden N, DaSilva C, Cohn D, Massaad R, Scott BB, Verbruggen N, Gurner D, Miller D-I, Blair ML, Polis AB, Stoch SA, Santora A, Lombardi A, Leung AT, Kafman KD, Sabatine MS, LOFT investigators. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicenter, randomised, double-blind, placebo-controlled trial and LOFT Extension study. *Lancet Diabetes Endocrinol* 2019 7(12) 899-911.
104. Therkildsen J, Winther S, Nissen L, Jørgensen HS, Thygesen J, Ivarsen P, Frost L, Isaksen C, **Langdahl BL,** Hauge EM, Böttcher M. Sex differences in the association between bone mineral density and coronary artery disease in patients referred for cardiac computed tomography. *J Clin Densitom* 2021 24(1) 55-66.
105. Bjerre ED, Petersen TH, Jørgensen AB, Johansen C, Krstrup P, **Langdahl B,** Poulsen MH, Madsen SS, Østergren PB, Borre M, Rørth M, Brasso K, Midtgaard J. Community-based football in men with prostate cancer: 1-year follow-up on a pragmatic, multicenter randomized controlled trial. *PLoS Med* 2019 1002936.
106. Keller KK, Thomsen JS, Stengaard-Pedersen K, Therkildsen J, Nielsen AW, Schiøtz-Christensen B, Svendsen L, Graakjær M, Petersen PM, Unger B, Kjær SG, **Langdahl BL,** Hauge EM. One-year progression of erosive disease in patients with anti-citrullinated peptide antibodies and arthralgia. *Joint Bone Spine* 2020 87(2) 181-3.
107. Hepp N, Frederiksen AL, Dunø M, Jørgensen NR, **Langdahl B,** Vedtofte P, Hove HB, Hindsø K, Jensen JB. Multiple fractures and impaired bone fracture healing in a patient with pycnodysostosis and hypophosphatasia. *Calcif Tissue Int* 2019 105(6) 681-86
108. Valentin G, Pedersen SE, Christensen R, Friis K, Nielsen CP, Bhimjiyana A, Gregson CL, **Langdahl BL.** Socio-economic inequalities in fragility fracture outcomes: a systematic review and meta-analysis of prognostic observational studies. *Osteoporos Int* 2020 31(1) 31-42.
109. Hansen RL, **Langdahl BL,** Jørgensen PH, Petersen KK, Søballe K, Stilling M. Changes in perioperative bone mineral density and bone turnover markers after osseointegrated implant surgery: A cohort study of 20 transfemoral amputees with 30-months follow-up. *Prosthet Orthot Int* 2019 43(5) 508-18.
110. Hygum K, Starup-Linde J, **Langdahl BL.** Diabetes and bone. *Osteoporos Sarcopenia* 2019 5(2) 29-37.
111. Hansen RL, **Langdahl BL,** Jørgensen PH, Petersen KK, Søballe K, Stilling M. Does migration of osseointegrated implants for transfemoral amputees predict later revision? A prospective 2-year radiostereometric analysis with 5-years clinical follow-up. *Orthop Traumatol Surg Res* 2019 105(5) 1013-20.
112. Linde KN, Madsen F, Puhakka KB, **Langdahl BL,** Søballe K, Krog-Mikkelsen I, Stilling M. Preoperative systemic bone quality does not affect tibial component migration in knee arthroplasty: A 2-year radiostereometric analysis of hundred consecutive patients. *J Arthroplasty* 2019 34(10) 2351-9.
113. Hygum K, Starup-Linde JK, Harsløf T, Jørgensen NR, Hartmann B, Holst JJ, **Langdahl B.** The diurnal variation of bone formation is attenuated in adult patients with type 2 diabetes. *Eur J Endocrinol* 2019 181(3) 221-31.
114. Hygum K, Harsløf T, **Langdahl B,** Starup-Linde J. Glucagon-like peptide-1 receptor agonists and fracture risk – limitations to current knowledge. *Osteoporos Int* 2019 30(8) 1709-10.
115. Sølling ASK, Harsløf T, **Langdahl B.** Current status of bone-forming therapies for the management of osteoporosis. *Drugs Aging* 2019 36(7) 625-38.
116. **Langdahl BL.** A clinical guideline on Paget's disease of bone – A guideline or a review? *J Bone Miner Res* 2019 34(4) 577-78.
117. Tei RMH, Plana-Ripoll O, Brink O, **Langdahl BL.** An optimised fracture liaison service model: Maintained diagnostic sensitivity despite reduced number of diagnostic tests performed. *Calcif Tissue Int.* 2019 104(6) 641-49.
118. Karasik D, Zillikens MC, Hsu YH, Aghdassi A, Akesson K, Amin N, Barroso I, Bennett DA, Bertram L, Bochud M, Borecki IB, Broer L, Buchman AS, Byberg L, Campbell H, Campos-Obando N, Cauley JA, Cawthon PM, Chambers JC, Chen Z, Cho NH, Choi HJ, Chou WC, Cummings SR, de Groot LCPGM, De Jager PL, Demuth I, Diatchenko L, Econs MJ, Eiriksdottir G, Enneman AW, Eriksson J, Eriksson JG, Estrada K, Evans DS, Feitosa MF, Fu M, Gieger C, Grallert H, Gudnason V, Lenore LJ, Hayward

- C, Hofman A, Homuth G, Huffman KM, Husted LB, Illig T, Ingelsson E, Ittermann T, Jansson JO, Johnson T, Biffar R, Jordan JM, Jula A, Karlsson M, Khaw KT, Kilpeläinen TO, Klopp N, Kloth JSL, Koller DL, Kooner JS, Kraus WE, Kritchevsky S, Kutalik Z, Kuulasmaa T, Kuusisto J, Laakso M, Lahti J, Lang T, **Langdahl BL**, Lerch MM, Lewis JR, Lill C, Lind L, Lindgren C, Liu Y, Livshits G, Ljunggren Ö, Loos RJF, Lorentzon M, Luan J, Luben RN, Malkin I, McGuigan FE, Medina-Gomez C, Meitinger T, Melhus H, Mellström D, Michaëlsson K, Mitchell BD, Morris AP, Mosekilde L, Nethander M, Newman AB, O'Connell JR, Oostra BA, Orwoll ES, Palotie A, Peacock M, Perola M, Peters A, Prince RL, Psaty BM, Rääkkönen K, Ralston SH, Ripatti S, Rivadeneira F, Robbins JA, Rotter JI, Rudan I, Salomaa V, Satterfield S, Schipf S, Shin CS, Smith AV, Smith SB, Soranzo N, Spector TD, Stancáková A, Stefansson K, Steinhagen-Thiessen E, Stolk L, Streeten EA, Styrkarsdóttir U, Swart KMA, Thompson P, Thomson CA, Thorleifsson G, Thorsteinsdóttir U, Tikkani E, Tranah GJ, Uitterlinden AG, van Duijn CM, van Schoor NM, Vandenput L, Vollenweider P, Völzke H, Wactawski-Wende J, Walker M, Wareham N, Waterworth D, Weedon MN, Wichmann HE, Widen E, Williams FMK, Wilson JF, Wright NC, Yerges-Armstrong LM, Yu L, Zhang W, Zhao JH, Zhou Y, Nielson CM, Harris TB, Demissie S, Kiel DP, Ohlsson. Disentangling the genetics of lean mass. *Am J Clin Nutr* 2019 109(2) 276-87.
119. Madsen LR, Espersen R, Ornstrup MJ, Jørgensen NR, **Langdahl BL**, Richelsen B. Bone Health in patients with type 2 diabetes treated by Roux-en-Y gastric bypass and the role of diabetes remission. *Obes Surg* 2019 29(6) 1823-31.
 120. Therkildsen J, Winther S, Nissen L, Jørgensen HS, Thygesen J, Ivarsen P, Frost L, **Langdahl BL**, Hauge EM, Böttcher M. Feasibility of opportunistic screening for low thoracic bone mineral density in patients referred for routine cardiac CT. *J Clin Densitom* 2018 S1094-6950(18)30225-7
 121. Koldkjær Sølling AS, Harsløf T, **Langdahl B**. Treatment with zoledronic acid subsequent to odanacatib prevents bone loss in postmenopausal women with osteoporosis. *Osteoporosis Int* 2019 30(5) 995-1002.
 122. Olsen A, Kyrø C, Schwarz P, Vestergaard P, Lidegaard Ø, Hermann P, **Langdahl B**, Beck-Jensen JE, Abrahamsen B, Harsløf T. Phytoestrogens as a dietary supplement. *Ugeskr Laeger* 2018 180(49).
 123. Andersen JD, Bünger MH, Rahbek O, Hald JD, Harsløf T, **Langdahl BL**. Do femoral fractures in adult patients with osteogenesis imperfecta imitate atypical femoral fractures? A case series. *Osteoporosis Int* 2019 30(2) 513-17.
 124. **Langdahl B**. Treatment breaks in long-term management of osteoporosis. *Eur J Endocrinol* 2019 180(1) R29-R35.
 125. **Langdahl BL**. Osteoporosis treatment: Bone-forming agents. In *Encyclopedia of Endocrine Diseases*, 2nd edition 2019 275-280.
 126. **Langdahl BL**. Thyroid disease and bone. In *Encyclopedia of Endocrine Diseases*, 2nd edition 2019 787-791.
 127. Thuesen KJ, Gjørup H, Hald JD, Schmidt M, Harsløf T, **Langdahl B**, Haubek D. The dental perspective on osteogenesis imperfecta in a Danish adult population. *BMC Oral Health* 2018 18(1):175.
 128. Silverman S, **Langdahl BL**, Fujiwara S, Saag K, Napoli N, Soen S, Enomoto H, Melby TE, Disch DP, Marin F, Krege JH. Reduction of hip and other fractures in patients receiving teriparatide in real-world clinical practice: Integrated analysis of four prospective observational studies. *Calcif Tissue Int* 2019 104(2) 193-200.
 129. **Langdahl BL**, Andersen JD: Treatment of osteoporosis: Unmet needs and emerging solutions. *J Bone Metab* 2018 25(3):133-140.
 130. Starup-Linde J, Hygum K, **Langdahl BL**. Skeletal fragility in type 2 diabetes mellitus. *Endocrinol Metab (Seoul)* 2018 33(3):339-351.
 131. Tei RMH, Ramlau-Hansen CH, Plana-Ripoll O, Brink O, **Langdahl BL**. OFELIA: Prevalence of osteoporosis in fragility fracture patients. *Calcif Tissue Int* 2019 104(1) 102-144.
 132. Ørnstrup MJ, Kjær TN, Harsløf T, Jørgensen NR, Pedersen SB, **Langdahl BL**. Comparison of bone turnover markers in peripheral blood and bone marrow aspirate. *Bone* 2018 116:315-320
 133. Sølling ASK, Harsløf T, **Langdahl BL**. Antistofbaseret behandling af osteoporose – behandling af osteoporose med denosumab og romosozumab. *Tandlægebladet* 2018 1389.
 134. Hald JD, Folkestad L, Swan CZ, Wanscher J, Schmidt M, Gjørup H, Haubek D, Leonhard CH, Larsen DA, Hjortdal JØ, Harsløf T, Duno M, Lund AM, Jensen JB, Brixen K, **Langdahl B**. Osteogenesis imperfecta and the teeth, eyes, and ears – a study of non-skeletal phenotypes in adults. *Osteoporosis Int* 2018 29(12) 2781-89.
 135. **Langdahl BL**, Silverman S, Fujiwara S, Saag K, Napoli N, Soen S, Enomoto H, Melby TE, Disch DP, Marin F, Krege JH. Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: Integrated analysis of 4 prospective observational studies. *Bone* 2018 116:58-66.
 136. Sølling ASK, Harsløf T, **Langdahl B**. The clinical potential of romosozumab for the prevention of fractures in postmenopausal women with osteoporosis. *Ther adv Musculoskelet Dis* 2018 10(5-6):105-115.
 137. **Langdahl BL**. Is there a place for bone turnover markers in the management of osteoporosis? *J Bone Miner Res* 2018 33(7):1197-98.

138. Blavnsfeldt AG, de Thurah A, Thomsen MD, Tarp S, **Langdahl B**, Hauge EM. The effect of glucocorticoids on bone mineral density in patients with rheumatoid arthritis: A systematic review and meta-analysis of randomized, controlled trials. *Bone* 2018 114:172-180.
139. Napoli N, **Langdahl BL**, Ljunggren Ö, Lespessailles E, Kapetanios G, Kocjan T, Nikolic T, Eiken P, Petto H, Moll T, Lindh E, Marin F. Effects of teriparatide in patients with osteoporosis in clinical practice: 42-month results during and after discontinuation of treatment from the European extended Forsteo observational study (ExFOS). *Calcif Tissue Int* 2018 103(4) 359-71.
140. Jensen AL, Wind G, **Langdahl BL**, Lomborg K. The impact of multifaceted osteoporosis group education on patients' decision-making regarding treatment options and lifestyle changes. *J Osteoporos* 2018, 9703602
141. Cundy T, Dray M, Delahunt J, Hald JD, **Langdahl B**, Li C, Szybowska M, Mohammed S, Duncan EL, McInerney-Leo AM, Wheeler PG, Roschger P, Klaushofer K, Rai J, Weis M, Eyre D, Schwarze U, Byers PH. Mutations that alter the Carboxy-Terminal propeptide cleavage site of the chains of type I procollagen are associated with a unique osteogenesis imperfect phenotype. *J Bone Miner Res* 2018 33(7) 1260-71.
142. Sølling ASK, Tougaard B, Harsløf T, **Langdahl B**, Kongsbak Brockstedt H, Byg KE, Ivarsen P, Karstoft Ystrøm I, Holden Mose F, Lissel Isaksson G, Steen Svarer Hansen M, Nagarajah S, Ejersted C, Bendstrup E, Rejnmark L. Non-parathyroid hypercalcemia associated with paraffin oil injection in 12 younger male bodybuilders. *Eur J Endocrinol* 2018 178(6) K29-K37.
143. Bendixen KH, Gjørup H, Baad-Hansen L, Dahl Hald J, Harsløf T, Schmidt MH, **Langdahl BL**, Haubek D. Temporomandibular disorders and psychosocial status in osteogenesis imperfect – a cross-sectional study. *BMC Oral Health*. 2018 Mar 7;18(1):35.
144. **Langdahl BL**, Ralston SH. How basic science discoveries have shaped the treatment of bone and mineral disorders. *J Bone Miner Res* 2017 32(12) 2324-30.
145. Alonso N, Estrada K, Albagha OME, Herrera L, Reppe S, Olstad OK, Gautvik KM, Ryan NM, Evans KL, Nielson CM, Hsu YH, Kiel DP, Markozannes G, Ntzani EE, Evangelou E, Feenstra B, Liu X, Melbye M, Masi L, Brandi ML, Riches P, Daroszewska A, Olmos JM, Valero C, Castillo J, Riancho JA, Husted LB, **Langdahl BL**, Brown MA, Duncan EL, Kaptoge S, Khaw KT, usategui-Martin R, Del Pino-Montes J, Gonzales-Sarmiento R, Lewis JR, Prince RL, D'Amelio P, Garcia-Giralt N, Nogues X, Mencej-Bedrac S, Marc J, Wolstein O, Eisman JA, Oei L, Medina-Gomez C Schraut KE, Navarro P, Wilson JF, Davies G, Starr J, Deary I, Tanaka T, Ferrucci L, Gianfrancesco F, Gennari L, Lucas G, Elosua R, Uitterlinden AG, Rivadeneira F, Ralston SH: Identification of a novel locus on chromosome 2q13, which predisposes to clinical vertebral fractures independently of bone density. *Ann Rheum Dis* 2017 77(3):378-85.
146. Starup-Linde J, Hygum K, Harsløf T, **Langdahl BL**. Indications of increased vertebral fracture risk in patients with type 2 diabetes. *J Bone Miner Res* 2017 33(1) 182
147. Ørnstrup MJ, Brüel A, Thomsen JS, Harsløf T, **Langdahl BL**, Pedersen SB. Long-term high-dose resveratrol supplementation reduces bone mass and fracture strength in rats. *Calcif Tissue Int* 2017 102(3) 337-347
148. Hygum K, **Langdahl BL**, Starup-Linde J. Disentangling the association between diabetes and bone disease. *Lancet Diabetes Endocrinol*. 2017 5(10) 769.
149. Linde KN, Puhakka KB, **Langdahl BL**, Søballe K, Krog-Mikkelsen I, Madsen F, Stilling M. Bone Mineral Density is Lower in Patients with Severe Knee Osteoarthritis and Attrition. *Calcif Tissue Int*. 2017 101(6) 593-601.
150. Keller KK, Thomsen JS, Stengaard-Pedersen K, Nielsen AW, Schiøttz-Christensen B, Svendsen L, Graakjær M, Petersen PM, Unger B, Kjær SG, **Langdahl BL**, Hauge EM. Local bone loss in patients with anti-citrullinated peptide antibody and arthralgia, evaluated with high-resolution peripheral quantitative computed tomography. *Scand J Rheumatol*. 2018 47(2) 110-116.
151. Tsourdi E, **Langdahl B**, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Guafabens N, Obermayer-Pietsch B, Ralston SH, Eastell R, Zillikens MC. Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS. *Bone* 2017 105:11-17.
152. Zillikens MC, Demissie S, Hsu YH, Yerges-Armstrong LM, Chou WC, Stolk L, Livshits G, Broer L, Johnson T, Koller DL, Kutalik Z, Luan J, Malkin I, Ried JS, Smith AV, Thorleifsson G, Vandenput L, Hua Zhao J, Zhang W, Aghdassi A, Åkesson K, Amin N, Baier LJ, Barroso I, Bennett DA, Bertram L, Biffar R, Bochud M, Boehnke M, Borecki IB, Buchman AS, Byberg L, Campbell H, Campos Obanda N, Cauley JA, Cawthon PM, Cederberg H, Chen Z, Cho NH, Jin Choi H, Claussnitzer M, Collins F, Cummings SR, De Jager PL, Demuth I, Dhonukshe-Rutten RAM, Diatchenko L, Eiriksdottir G, Enneman AW, Erdos M, Eriksson JG, Eriksson J, Estrada K, Evans DS, Feitosa MF, Fu M, Garcia M, Gieger C, Girke T, Glazer NL, Grallert H, Grewal J, Han BG, Hanson RL, Hayward C, Hofman A, Hoffman EP, Homuth G, Hsueh WC, Hubal MJ, Hubbard A, Huffman KM, Husted LB, Illig T, Ingelsson E, Ittermann T, Jansson JO, Jordan JM, Julia A, Karlsson M, Khaw KT, Kilpeläinen TO, Klopp N, Kloth JSL, Koistinen HA, Kraus WE, Kritchevsky S, Kuulasmaa T, Kuusisto J, Laakso M, Lahti J, Lang T, **Langdahl BL**, Launer LJ, Lee JY, Lerch MM, Lewis JR, Lind L, Lindgren C, Liu Y, Liu T, Liu Y, Ljunggren Ö, Lorentzon M, Luben RN, Maixner W, McGuigan FE, Medina-Gomez C, Meitinger T, Melhus H, Mellström D, Melov S, Michaëlsson K, Mitchell BD, Morris AP, Mosekilde L, Newman A, Nielson CM, O'Connell JR, Oostra BA, Orwoll ES, Palotie A, Parker S, Peacock M, Perola M, Peters A,

- Polasek O, Prince RL, Rääkkönen K, Ralston SH, Ripatti S, Robbins JA, Rotter JI, Rudan I, Salomaa V, Satterfield S, Schadt EE, Schipf S, Scott L, Sehmi J, Shen J, Soo Shin C, Sigurdsson G, Smith S, Soranzo N, Stančáková A, Steinhagen-Thiessen E, Streeten EA, Styrkarsdóttir U, Swart KMA, Tan ST, Tarnopolsky MA, Thompson P, Thomson CA, Thorsteinsdóttir U, Tikkanen E, Tranah GJ, Tuomilehto J, van Schoor NM, Verma A, Vollenweider P, Völzke H, Wactawski-Wende J, Walker M, Weedon MN, Welch R, Wichmann HE, Widen E, Williams FMK, Wilson JF, Wright NC, Xie W, Yu L, Zhou Y, Chambers JC, Döring A, van Duijn CM, Econs MJ, Gudnason V, Kooner JS, Psaty BM, Spector TD, Stefansson K, Rivadeneira F, Uitterlinden AG, Wareham NJ, Ossowski V, Waterworth D, Loos RJF, Karasik D, Harris TB, Ohlsson C, Kiel DP. Large meta-analysis of genome-wide association studies identifies five loci for lean body mass. *Nat Commun*. 2017 8(1):80.
153. Hald JD, Folkestad L, Harsløf T, Brixen K, **Langdahl B**. Health-Related Quality of Life in Adults with Osteogenesis Imperfecta. *Calcif Tissue Int*. 2017 101(5) 473-78.
 154. **Langdahl BL**, Libanati C, Crittenden DB, Bolognese MA, Brown JP, Daizadeh NS, Dokoupilova E, Engelke K, Finkelstein JS, Genant HK, Goemare S, Hyldstrup L, Jodar-Gimeno E, Keaveny TM, Kendler D, Lakatos P, Maddox J, Malouf J, Massari FE, Molina, JF, Ulla MR, Grauer A. Romosozumab or teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomized open-label phase 3 trial. *Lancet Diabetes Endocrinol* 2017 390(10102) 1585-94.
 155. Keaveny TM, Crittenden DB, Bolognese MA, Genant HK, Engelke K, Oliveri B, Brown JP, **Langdahl BL**, Yan C, Grauer A, Libanati C. Greater Gains in Spine and Hip Strength for Romosozumab Compared to Teriparatide in Postmenopausal Women With Low Bone Mass. *J Bone Miner Res*. 2017 32(9) 1956-62.
 156. Hansen RL, **Langdahl BL**, Jørgensen PH, Petersen KK, Søballe K, Stilling M. Bone Mineral Density Measurements Around Osseointegrated Implants: A Precision Study and Validation of Scan Protocol for Transfemoral Amputees. *J Clin Densitom*. 2018 21:244-51.
 157. Hadji P, Aapro MS, Body JJ, Gnani M, Brandi ML, Reginster JY, Zillikens MC, Glüer CC, de Villiers T, Baber R, Roodman GD, Cooper C, **Langdahl B**, Palacios S, Kanis J, Al-Daghri N, Nogues X, Eriksen EF, Kurth A, Rizzoli R, Coleman RE. Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. *J Bone Oncol*. 2017 7:1-12.
 158. **Langdahl BL**. Osteoporosis in premenopausal women. *Curr Opin Rheumatol*. 2017 29(4):410-415.
 159. **Langdahl B**, Ferrari S, Dempster DW. Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis. *Ther Adv Musculoskelet Dis*. 2016 Dec;8(6):225-235.
 160. Hjorth MH, Kold S, Søballe K, **Langdahl BL**, Nielsen PT, Christensen PH, Stilling M. Preparation of the Femoral Bone Cavity for Cementless Stems: Broaching vs Compaction. A Five-Year Randomized Radiostereometric Analysis and Dual Energy X-Ray Absorption Study. *J Arthroplasty*. 2016 32(6):1894-1901.
 161. Hygum K, Starup-Linde J, Harsløf T, Vestergaard P, **Langdahl BL**. MECHANISMS IN ENDOCRINOLOGY: Diabetes mellitus, a state of low bone turnover - a systematic review and meta-analysis. *Eur J Endocrinol*. 2017 176(3):R137-R157.
 162. Khan AA, Morrison A, Kendler DL, Rizzoli R, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, **Langdahl BL**, Dabagh RA, Davison KS, Sándor GK, Josse RG, Bhandari M, El Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP, Compston J; International Task Force on Osteonecrosis of the Jaw. Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ. *J Clin Densitom*. 2017 20(1):8-24.
 163. Harsløf T, Sikjaer T, Mosekilde L, **Langdahl BL**, Rejnmark L. Correlations Between Changes in Undercarboxylated Osteocalcin and Muscle Function in Hypoparathyroidism. *Int J Endocrinol Metab*. 2016 14(3):e38440.
 164. Folkestad L, Hald JD, Gram J, **Langdahl BL**, Hermann AP, Diederichsen AC, Abrahamsen B, Brixen K: Cardiovascular disease in patients with osteogenesis imperfecta – a nationwide, register-based cohort study. *Int J Cardiol* 2016 225:250-57
 165. Eastell R, O'Neill TW, Hofbauer LC, **Langdahl B**, Reid IR, Gold DT, Cummings SR: Postmenopausal osteoporosis. *Nat Rev Dis Primers* 2016 2:16069
 166. Rønn SH, Harsløf T, Pedersen SB, **Langdahl B**: Vitamin K2 (menaquinone-7) prevents age-related deterioration of trabecular bone microarchitecture at the tibia in postmenopausal women. *Eur J Endocrinol* 2016 175(6):541-549.
 167. Lhaneche L, Hald JD, Domingues A, Hannouche D, Delepine M, Zelenika D, Boland A, Ostertag A, Cohen-Solal M, **Langdahl BL**, Harsløf T, Vernejoul MC, Geoffroy V, Jehan F: Variations of SOST mRNA expression in human bone are associated with DNA polymorphism and DNA methylation in the SOST gene. *Bone* 2016 92:107-15
 168. Folkestad L, Hald JD, Ersbøll AK, Gram J, Hermann AP, **Langdahl B**, Abrahamsen B, Brixen K: Fracture rates and fracture sites in patients with osteogenesis imperfecta: A nation-wide register-based cohort study. *J Bone Miner Res* 2017 32(1) 125-134.

169. Folkestad L, Hald JD, Canudas-Romo V, Gram J, Hermann AP, **Langdahl B**, Abrahamsen B, Brixen K: Mortality and causes of death in patients with osteogenesis imperfecta. A register-based nationwide cohort study. *J Bone Miner Res* 2016 31(12): 2159-66.
170. Hald JD, Folkestad L, Harsløf T, Lund AM, Duno M, Jensen JB, Neghabat S, Brixen K, **Langdahl B**: Skeletal phenotypes in adult patient with osteogenesis imperfecta – correlations with COL1A1/COL1A2 genotype and collagen structure. *Osteoporos Int* 2016 27(11):3331-41
171. Harsløf T, **Langdahl BL**: New Horizons in osteoporosis therapies. *Curr Opin Pharmacol* 2016 14:38-42
172. Sølling ASK, Harsløf T, Kaal A, Rejnmark L, **Langdahl BL**: Hypercalcemia after discontinuation of long-term denosumab treatment. *Osteoporos Int* 2016 27(7): 2383-6
173. Jensen AL, Lomborg K, **Langdahl BL**, Wind G: Managing a Bone Healthy Lifestyle after attending Multifaceted Group Education. *Calcif Tissue Int.* 2016 99(3):272-81
174. **Langdahl BL**, Ljunggren Ö, Benhamou CL, Marin F, Kapetanios G, Kocjan T, Lespessailles E, Napoli N, Nikolic T, Petto H, Moll T, Lindh E: Fracture Rate, Quality of Life and Back Pain in Patients with Osteoporosis Treated with Teriparatide: 24-Month Results from the Extended Forsteo Observational Study (ExFOS). *Calcif Tissue Int.* 2016 99(3):259-71
175. Ornstrup MJ, Harsløf T, Sørensen L, Stenkjær L, **Langdahl BL**, Pedersen SB: Resveratrol increases osteoblast differentiation in vitro independently of inflammation. *Calcif Tissue Int.* 2016 99(2):155-63
176. Starup-Linde J, Lykkeboe S, Gregersen S, Hauge EM, **Langdahl BL**, Handberg A, Vestergaard P. Differences in biochemical bone markers by diabetes type and the impact of glucose. *Bone* 2016 83:149-55
177. Starup-Linde J, Lykkeboe S, Gregersen S, Hauge EM, **Langdahl BL**, Handberg A, Vestergaard P. Bone structure and predictors of fracture in type 1 and type 2 diabetes. *J Clin Endocrinol Metab.* 2016 101(3):928-36
178. Ornstrup MJ, Kjær TN, Harsløf T, Stødkilde-Jørgensen H, Hougaard DM, Cohen A, Pedersen SB, **Langdahl BL**. Adipose tissue, estradiol levels, and bone health in obese men with metabolic syndrome. *Eur J Endocrinol* 2015 172(2):205-16
179. Khan A, Morrison A, Hanley D, Felsenberg D, McCauley L, O’Ryan F, Reid I, Ruggiero S, Taguchi A, Tetradis S, Watts N, Brandi M, Peters E, Guise T, Eastell R, Cheung A, Morin S, Masri B, Cooper C, Morgan S, Obermayer-Pietsch B, **Langdahl B**, Al Dabagh R, Davison K, Kendler D, Sándor G, Josse R, Bhandari M, El Rabbany M, Pierroz D, Sulimani R, Saunders D, Brown J, Compston J; behalf of the International Task Force on Osteonecrosis of the Jaw. Diagnosis and Management of Osteonecrosis of the Jaw: A systematic Review and International Consensus. *J Bone Min Res* 2015 30(1):3-23
180. Hald JD, Evangelou E, **Langdahl BL**, Ralston SH: Bisphosphonates for the Prevention of Fractures in Osteogenesis Imperfecta: Meta-Analysis of Placebo-Controlled Trials. *J Bone Min Res* 2015 30(5):929-933
181. **Langdahl BL**, Teglbaerg CS, Ho PR, Chapurlat R, Czerwinski E, Kendler DL, Reginster JY, Kivitz A, Lewiecki EM, Miller PD, Bolognese MA, McClung MR, Bone HG, Ljunggren Ö, Abrahamsen B, Gruntmanis U, Yang YC, Wagman RB, Mirza F, Siddhanti S, Orwoll E. A 24-month Study Evaluating the Efficacy and Safety of Denosumab for the Treatment of Men With Low Bone Mineral Density: Results From the ADAMO Trial. *J Clin Endocrinol Metab.* 2015 100(4):1335-42
182. Bendix M, Dige A, Deleuran B, Dahlerup JF, Peter Jørgensen S, Bartels LE, Husted LB, Harsløf T, **Langdahl B**, Agnholt J: Flow cytometry detection of vitamin D receptor changes during vitamin D treatment in Crohn’s disease. *Clin Exp Immunol* 2015 181(1):19-28
183. Pedersen MA, Gregersen M, **Langdahl BL**, Damsgaard EMS: Frail elderly hip fracture patients and vitamin D. *J Geront Geriatr Res* 2014 3(5):180
184. Zheng HF, Forgetta V, Hsu YH, Estrada K, Rosello-Diez A, Leo PJ, Dahia CL, Park-Min KH, Tobias JH, Kooperberg C, Kleinman A, Stykarsdottir U, Liu CT, Uggla C, Evans DS, Nielson CM, Walter K, Pettersson-Kymmer U, McCarthy S, Eriksson J, Kwan T, Jhamai M, Trajanoska K, Memari Y, Min J, Huang J, Danecek P, Wilmut B, Li R, Chou WC, Mokry LE, Moayyeri A, Claussnitzer M, Cheng CH, Cheung W, Medina-Gómez C, Ge B, Chen SH, Choi K, Oei L, Fraser J, Kraaij R, Hibbs MA, Gregson CL, Paquette D, Hofman A, Wibom C, Tranah GJ, Marshall M, Gardiner BB, Cremin K, Auer P, Hsu L, Ring S, Tung JY, Thorleifsson G, Enneman AW, van Schoor NM, de Groot LC, van der Velde N, Melin B, Kemp JP, Christiansen C, Sayers A, Zhou Y, Calderari S, van Rooij J, Carlson C, Peters U, Berlivet S, Dostie J, Uitterlinden AG, Williams SR, Farber C, Grinberg D, LaCroix AZ, Haessler J, Chasman DI, Giulianini F, Rose LM, Ridker PM, Eisman JA, Nguyen TV, Center JR, Nogues X, Garcia-Giralt N, Launer LL, Gudnason V, Mellström D, Vandenput L, Amin N, van Duijn CM, Karlsson MK, Ljunggren Ö, Svensson O, Hallmans G, Rousseau F, Giroux S, Bussière J, Arp PP, Koromani F, Prince RL, Lewis JR, **Langdahl BL**, Pernille Hermann A, Jensen JB, Kaptoge S, Khaw KT, Reeve J, Formosa MM, Xuereb-Anastasi A, Åkesson K, McGuigan FE, Garg G, Olmos JM, Zarrabeitia MT, Riancho JA, Ralston SH, Alonso N, Jiang X, Goltzman D, Pastinen T, Grundberg E, Gauguier D, Orwoll ES, Karasik D, Davey-Smith G; AOGC Consortium, Smith AV, Siggeirsdottir K, Harris TB, Carola Zillikens M, van Meurs JB, Thorsteinsdottir U, Maurano MT, Timpson NJ, Soranzo N, Durbin R, Wilson SG, Ntzani EE, Brown MA, Stefansson K, Hinds DA, Spector T, Adrienne Cupples L, Ohlsson C, Greenwood CM; UK10K Consortium, Jackson RD, Rowe DW, Loomis CA, Evans DM, Ackert-Bicknell

- CL, Joyner AL, Duncan EL, Kiel DP, Rivadeneira F, Richards JB. Whole-genome sequencing identifies EN1 as a determinant of bone density and fracture. *Nature* 2015 526(7571):112-7
185. Christensen DH, Horváth-Puhó E, Schmidt M, Christiansen CF, Pedersen L, **Langdahl BL**, Thomsen RW. The impact of preadmission oral bisphosphonate use on 30-day mortality following stroke: a population-based cohort study of 100,043 patients. *Clin Epidemiol.* 2015 24(7):381-9
 186. Duong LT, Leung AT, **Langdahl B**. Cathepsin K Inhibition: A New Mechanism for the Treatment of Osteoporosis. *Calcif Tissue Int.* 2016 98(4): 381-97
 187. Harsløf T, Sikjær T, Sørensen L, Pedersen SB, Mosekilde L, **Langdahl BL**, Rejnmark L. The Effect of Treatment With PTH on Undercarboxylated Osteocalcin and Energy Metabolism in Hypoparathyroidism. *J Clin Endocrinol Metab.* 2015 100(7):2758-62
 188. Langdahl BL. New treatments of osteoporosis. *Osteoporosis & Sarcopenia* 2015 1(1):4-21
 189. Hygum K, Wulff CN, Harsløf T, Boysen AK, Rossen PB, **Langdahl BL**, Safwat AA. Hypercalcemia in metastatic GIST caused by systemic elevated calcitriol: a case report and review of the literature. *BMC Cancer* 2015 15:788
 190. Hansen L, Petersen KD, Eriksen SA, **Langdahl BL**, Eiken PA, Brixen K, Abrahamsen B, Jensen JE, Harsløf T, Vestergaard P. Subsequent fracture rates in a nationwide population-based cohort study with a 10-year perspective. *Osteoporos Int.* 2015 26(2):513-9
 191. Jensen AL, Lomborg K, Wind G, **Langdahl BL**: Effectiveness and characteristics of multifaceted osteoporosis group education-a systematic review. *Osteoporos Int.* 2014 25(4):1209-24
 192. Oei L, Hsu YH, Stykarsdottir U, Eussen BH, de Klein A, Peters MJ, Halldorsson B, Liu CT, Alonso N, Kaptoge SK, Thorleifsson G, Hallmans G, Hocking LJ, Husted LB, Jameson KA, Kruk M, Lewis JR, Patel MS, Scollen S, Svensson O, Trompet S, van Schoor NM, Zhu K, Buckley BM, Cooper C, Ford I, Goltzman D, González-Macías J, **Langdahl BL**, Leslie WD, Lips P, Lorenc RS, Olmos JM, Pettersson-Kymmer U, Reid DM, Riancho JA, Slagboom PE, Garcia-Ibarbia C, Ingvarsson T, Johannsdottir H, Luben R, Medina-Gómez C, Arp P, Nandakumar K, Palsson ST, Sigurdsson G, van Meurs JB, Zhou Y, Hofman A, Jukema JW, Pols HA, Prince RL, Cupples LA, Marshall CR, Pinto D, Sato D, Scherer SW, Reeve J, Thorsteinsdottir U, Karasik D, Richards JB, Stefansson K, Uitterlinden AG, Ralston SH, Ioannidis JP, Kiel DP, Rivadeneira F, Estrada K: A genome-wide copy number association study of osteoporotic fractures points to the 6p25.1 locus. *J Med Genet* 2014 51(2):122-31
 193. McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, **Langdahl BL**, Reginster JY, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang YC, Libanati C, Bone HG: Romosozumab in postmenopausal women with low bone mineral density. *N Engl J Med* 2014 370(5):412-20
 194. Oei L, Estrada K, Duncan EL, Christiansen C, Liu CT, **Langdahl BL**, Obermayer-Pietsch B, Riancho JA, Prince RL, van Schoor NM, McCloskey E, Hsu YH, Evangelou E, Ntzani E, Evans DM, Alonso N, Husted LB, Valero C, Hernandez JL, Lewis JR, Kaptoge SK, Zhu K, Cupples LA, Medina-Gómez C, Vandenput L, Kim GS, Hun Lee S, Castaño-Betancourt MC, Oei EH, Martinez J, Daroszewska A, van der Klift M, Mellström D, Herrera L, Karlsson MK, Hofman A, Ljunggren Ö, Pols HA, Stolk L, van Meurs JB, Ioannidis JP, Zillikens MC, Lips P, Karasik D, Uitterlinden AG, Stykarsdottir U, Brown MA, Koh JM, Richards JB, Reeve J, Ohlsson C, Ralston SH, Kiel DP, Rivadeneira F: Genome-wide association study for radiographic vertebral fractures: a potential role for the 16q24 BMD locus. *Bone* 2014 59:20-7
 195. Torekov S, Harsløf T, Rejnmark L, Eiken P, Jensen J, Herman A, Hansen T, Pedersen O, Holst J, **Langdahl B**: A Functional Amino Acid Substitution in the Glucose-dependent Insulinotropic Polypeptide-Receptor (GIPR) Gene is Associated with Lower Bone Mineral Density and Increased Fracture risk. *J Clin Endocrinol Metab.* 2014 99(4):E729-33
 196. Lindahl K, **Langdahl B**, Ljunggren O, Kindmark A: Treatment of osteogenesis imperfecta in adults. *Eur J Endocrinol* 2014 171(2):R79-90
 197. Ljunggren O, Benhamou CL, Dekker J, Kapetanios G, Kocjan T, **Langdahl BL**, Napoli N, Petto H, Nikolic T, Lindh E: Study description and baseline characteristics of the population enrolled in a multinational observational study of extended teriparatide use (ExFOS). *Curr Med Res Opin* 2014 30(8):1607-16
 198. Vimalaswaran KS, Cavadino A, Berry DJ; LifeLines Cohort Study investigators, Jorde R, Dieffenbach AK, Lu C, Alves AC, Heerspink HJ, Tikkanen E, Eriksson J, Wong A, Mangino M, Jablonski KA, Nolte IM, Houston DK, Ahluwalia TS, van der Most PJ, Pasko D, Zgaga L, Thiering E, Vitart V, Fraser RM, Huffman JE, de Boer RA, Schöttker B, Saum KU, McCarthy MI, Dupuis J, Herzig KH, Sebert S, Pouta A, Laitinen J, Kleber ME, Navis G, Lorentzon M, Jameson K, Arden N, Cooper JA, Acharya J, Hardy R, Raitakari O, Ripatti S, Billings LK, Lahti J, Osmond C, Penninx BW, Rejnmark L, Lohman KK, Paternoster L, Stolk RP, Hernandez DG, Byberg L, Hagström E, Melhus H, Ingelsson E, Mellström D, Ljunggren O, Tzoulaki I, McLachlan S, Theodoratou E, Tiesler CM, Jula A, Navarro P, Wright AF, Polasek O; International Consortium for Blood Pressure (ICBP); Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium; Global Blood Pressure Genetics (Global BPGen) consortium; Caroline Hayward, Wilson JF, Rudan I, Salomaa V, Heinrich J, Campbell H, Price JF, Karlsson M, Lind L, Michaëlsson K, Bandinelli S, Frayling TM, Hartman CA, Sørensen TI, Kritchevsky SB, **Langdahl BL**, Eriksson JG, Florez JC, Spector TD, Lehtimäki T, Kuh D, Humphries SE, Cooper C, Ohlsson C, März W, de Borst MH, Kumari M, Kivimäki M, Wang TJ, Power C, Brenner H, Grimnes G, van der Harst P, Snieder H, Hingorani AD, Pilz S, Whittaker JC, Järvelin MR,

- Hyppönen E: Association of vitamin D status with arterial blood pressure and hypertension risk: a mendelian randomisation study. *Lancet Diabetes Endocrinol* 2014 2(9):719-29.
199. Ornstrup MJ, Harsløf T, Kjær TN, **Langdahl BL**, Pedersen SB: Resveratrol increases bone mineral density and bone alkaline phosphatase in obese men: A randomised placebo-controlled trial. *J Clin Endocrinol Metab* 2014 99(12):4720-9.
 200. Jensen TW, Hansen MS, Hørslev-Petersen K, Hyldstrup L, Abrahamsen B, **Langdahl B**, Zerahn B, Pødenphant J, Stengaard-Petersen K, Junker P, Ostergaard M, Lottenburger T, Ellingsen T, Andersen LS, Hansen I, Skjødt H, Pedersen JK, Lauridsen UB, Svendsen AJ, Tarp U, Lindegaard H, Jurik AG, Vestergaard A, Hetland ML; the Cimestra study group; Cimestra Study Group. Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial. *Ann Rheum Dis*. 2014 73(6):1123-9
 201. Pietraszek A, Hermansen K, Pedersen SB, **Langdahl BL**, Holst JJ, Gregersen S. Effects of a meal rich in medium-chain saturated fat on postprandial lipemia in relatives of type 2 diabetics. *Nutrition* 2013 29(7-8): 1000-6
 202. Andersen T, Christensen FB, **Langdahl BL**, Ernst C, Fruensgaard S, Ostergaard J, Andersen JL, Rasmussen S, Niedermann B, Høy K, Helmig P, Holm R, Egund N, Bünger C: Degenerative spondylolisthesis is associated with low spinal bone density: a comparative study between spinal stenosis and degenerative spondylolisthesis. *Biomed Res Int* 2013 123847
 203. Ljunggren O, Barrett A, Stoykov I, **Langdahl BL**, Lems WF, Walsh JB, Fahrleitner-Pammer A, Rajzbaum G, Jakob F, Karras D, Marin F: Effective osteoporosis treatment with teriparatide is associated with enhanced quality of life in postmenopausal women with osteoporosis: The European Forsteo Observational Study. *BMC Musculoskelet Disord*. 2013 14:251
 204. Harsløf T, Nielsen MF, Husted LB, Nyegaard M, Brixen K, Børglum AD, Mosekilde L, Andersen M, Rejnmark L, **Langdahl BL**: Polymorphisms of muscle genes are associated with bone mass and incident osteoporotic fractures in Caucasians. *Calcif Tissue Int* 2013 92(5):467-76
 205. Lekamwasam S, Adachi JD, Agnusdei D, Bilezikian J, Boonen S, Borgström F, Cooper C, Diez-Perez A, Eastell R, Hofbauer LC, Kanis JA, **Langdahl BL**, Lesnyak O, Lorenc R, McCloskey E, Messina OD, Napoli N, Obermayer-Pietsch B, Ralston SH, Sambrook PN, Silverman S, Sosa M, Stepan J, Suppan G, Wahl DA, Compston JE: Joint IOF-ECTS GIO Guidelines Working Group. An appendix to the 2012 IOF-ECTS guidelines for the management of glucocorticoid-induced osteoporosis. *Arch Osteoporos* 2012 7(1-2):25-30
 206. Frost M, Petersen I, Andersen T, **Langdahl B**, Buhl T, Christiansen L, Brixen K, Christensen K. Birth weight and adult bone metabolism are unrelated. Results from birth weight discordant monozygotic twins. *J Bone Miner Res*. 2013 28(12):2561-9
 207. Eiken PA, Brask-Lindemann D, Vestbo J, **Langdahl BL**, Abrahamsen B. Diagnosing and treating osteoporosis in patients with chronic obstructive pulmonary disease. *Ugeskr Laeger* 2012 174(47):2922-6
 208. Jørgensen NR, Husted LB, Skarratt KK, Stokes L, Tofteng CL, Kvist T, Jensen JE, Eiken P, Brixen K, Fuller S, Clifton-Bligh R, Gartland A, Schwartz P, **Langdahl BL**, Wiley JS: Single-nucleotide polymorphisms in the P2X7 receptor gene are associated with postmenopausal bone loss and vertebral fractures. *Eur J Hum Genet* 2012 20(6):675-81
 209. Karras D, Stoykov I, Lems WF, **Langdahl BL**, Ljunggren O, Barrett A, Walsh JB, Fahrleitner-Pammer A, Rajzbaum G, Jakob F, Marin: Effectiveness of teriparatide in postmenopausal women with osteoporosis and glucocorticoid use: 3-year results from the EFOS study. *J Rheumatol* 2012 39(3):600-609
 210. Walsh JB, Lems WF, Karras D, **Langdahl BL**, Ljunggren O, Fahrleitner-Pammer A, Barrett A, Rejzbaum G, Jakob F, Marin F: Effectiveness of teriparatide in women over 75 years of age with severe osteoporosis: 36-months results from the European Forsteo Observational Study (EFOS) *Calcif Tissue Int* 2012 90(5):373-83
 211. Folkestad L, Hald JD, Hansen S, Gram J, **Langdahl B**, Abrahamsen B, Brixen K: Bone geometry, density and microarchitecture in the distal radius and tibia in adults with osteogenesis imperfecta type-1 assessed by HR-pQCT. *J Bone Miner Res* 2012 27(6):1405-12
 212. Lekamwasam S, Adachi JD, Agnusdei D, Bilezikian J, Boonen S, Borgström F, Cooper C, Diez-Perez A, Eastell R, Hofbauer LC, Kanis JA, **Langdahl BL**, Lesnyak O, Lorenc R, McCloskey E, Messina OD, Napoli N, Obermayer-Pietsch B, Ralston SH, Sambrook PN, Silverman S, Sosa M, Stepan J, Suppan G, Wahl DA, Compston JE: Joint IOF-ECTS GIO Guidelines Working Group. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. *Osteoporosis Int* 2012 23(9):2257-76
 213. Husted LB, Harsløf T, Stenkjær L, Carstens M, Jørgensen NR, **Langdahl BL**. Functional polymorphisms in the P2X7 receptor gene are associated with osteoporosis. *Osteoporosis Int*. 2013 24(3):949-59
 214. **Langdahl BL**, Ralston SH: Diagnosis and management of primary hyperparathyroidism in Europe. *QJM* 2012 105(6):519-25
 215. Estrada K, Stykarsdottir U, Evangelou E, Hsu YH, Duncan EL, Ntzani EE, Oei L, Albagha OM, Amin N, Kemp JP, Koller DL, Li G, Liu CT, Minster RL, Moayyeri A, Vandenput L, Willner D, Xiao SM,

Yerges-Armstrong LM, Zheng HF, Alonso N, Eriksson J, Kammerer CM, Kaptoge SK, Leo PJ, Thorleifsson G, Wilson SG, Wilson JF, Aalto V, Alen M, Aragaki AK, Aspelund T, Center JR, Dailiana Z, Duggan DJ, Garcia M, Garcia-Giralt N, Giroux S, Hallmans G, Hocking LJ, Husted LB, Jameson KA, Khusainova R, Kim GS, Kooperberg C, Koromila T, Kruk M, Laaksonen M, Lacroix AZ, Lee SH, Leung PC, Lewis JR, Masi L, Mencej-Bedrac S, Nguyen TV, Nogues X, Patel MS, Prezeli J, Rose LM, Scollen S, Siggeirsdottir K, Smith AV, Svensson O, Trompet S, Trummer O, van Schoor NM, Woo J, Zhu K, Balcels S, Brandi ML, Buckley BM, Cheng S, Christiansen C, Cooper C, Dedoussis G, Ford I, Frost M, Goltzman D, González-Macías J, Kähönen M, Karlsson M, Khusnutdinova E, Koh JM, Kollia P, **Langdahl BL**, Leslie WD, Lips P, Ljunggren O, Lorenc RS, Marc J, Mellström D, Obermayer-Pietsch B, Olmos JM, Pettersson-Kymmer U, Reid DM, Riancho JA, Ridker PM, Rousseau F, Lagboom PE, Tang NL, Urreizti R, Van Hul W, Viikari J, Zarrabeitia MT, Aulchenko YS, Castano-Betancourt M, Grundberg E, Herrera L, Ingvarsson T, Johannsdottir H, Kwan T, Li R, Luben R, Medina-Gómez C, Th Palsson S, Reppe S, Rotter JI, Sigurdsson G, van Meurs JB, Verlaan D, Williams FM, Wood AR, Zhou Y, Gautvik KM, Pastinen T, Raychaudhuri S, Cauley JA, Chasman DI, Clark GR, Cummings SR, Danoy P, Dennison EM, Eastell R, Eisman JA, Gudnason V, Hofman A, Jackson RD, Jones G, Jukema JW, Khaw KT, Lehtimäki T, Liu Y, Lorentzon M, McCloskey E, Mitchell BD, Nandakumar K, Nicholson GC, Oostra BA, Peacock M, Pols HA, Prince RL, Raitakari O, Reid IR, Robbins J, Sambrook PN, Sham PC, Shuldiner AR, Tylavsky FA, van Duijn CM, Wareham NJ, Cupples LA, Econs MJ, Evans DM, Harris TB, Kung AW, Psaty BM, Reeve J, Spector TD, Streeten EA, Zillikens MC, Thorsteinsdottir U, Ohlsson C, Karasik D, Richards JB, Brown MA, Stefansson K, Uitterlinden AG, Ralston SH, Ioannidis JP, Kiel DP, Rivadeneira F. Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. *Nat Genet.* 2012 44(5):491-501

216. Rasmussen TA, Jensen D, Tolstrup M, Nielsen US, Erlandsen EJ, Birn H, Østergaard L, **Langdahl BL**, Laursen AL: Comparison of bone and renal effects in HIV-infected adults switching to Abacavir or Tenofovir based therapy in a randomized trial. *PLoS One* 2012, 7(3):e32445
217. Liu CT, Estrada K, Yerges-Armstrong LM, Amin N, Evangelou E, Li G, Minster RL, Carless MA, Kammerer CM, Oei L, Zhou Y, Alonso N, Dailiana Z, Eriksson J, García-Giralt N, Giroux S, Husted LB, Khusainova R, Koromila T, Kung AW, Lewis JR, Masi L, Mencej-Bedrac S, Nogues X, Patel MS, Prezeli J, Richards JB, Sham PC, Spector T, Vandenput L, Xiao SM, Zheng HF, Zhu K, Balcels S, Brandi ML, Frost M, Goltzman D, González-Macías J, Karlsson M, Khusnutdinova EK, Kollia P, **Langdahl BL**, Ljunggren O, Lorentzon M, Marc J, Mellström D, Ohlsson C, Olmos JM, Ralston SH, Riancho JA, Rousseau F, Urreizti R, Van Hul W, Zarrabeitia MT, Castano-Betancourt M, Demissie S, Grundberg E, Herrera L, Kwan T, Medina-Gómez C, Pastinen T, Sigurdsson G, Thorleifsson G, van Meurs JB, Blangero J, Hofman A, Liu Y, Mitchell BD, O'Connell JR, Oostra BA, Rotter JI, Stefansson K, Streeten EA, Stykarsdottir U, Thorsteinsdottir U, Tylavsky FA, Uitterlinden A, Cauley JA, Harris TB, Ioannidis JP, Psaty BM, Robbins JA, Zillikens MC, Vanduijn CM, Prince RL, Karasik D, Rivadeneira F, Kiel DP, Cupples LA, Hsu YH: Assessment of gene-by-sex interaction on bone mineral density. *J Bone Miner Res.* 2012 27(10):2051-64
218. **Langdahl B**, Binkley N, Bone H, Gilchrist N, Resch H, Portales JR, Denker A, Lombardi A, De Tillegem CL, Dasilva C, Rosenberg E, Leung A: Odanacatib in the treatment of postmenopausal women with low bone mineral density: 5 years of continued therapy in a phase 2 study. *J Bone Miner Res.* 2012 27(11):2251-8
219. Orwoll E, Tegljbærg CS, **Langdahl BL**, Chapurlat R, Czerwinski E, Kendler DL, Reginster JY, Kivitz A, Lewiecki EM, Miller PD, Bolognese MA, McClung MR, Bone HG, Ljunggren O, Abrahamsen B, Gruntmanis U, Yang YC, Wagman RB, Siddhanti S, Grauer A, Hall JW, Boonen S: A Randomized, Placebo-Controlled Study of the Effects of Denosumab for the Treatment of Men with Low Bone Mineral Density. *J Clin Endocrinol Metab.* 2012 97(9):3161-9
220. Boonen S, Reginster JY, Kaufman JM, Lippuner K, Zanchetta J, **Langdahl B**, Rizzoli R, Lipschitz S, Dimai HP, Witvrouw R, Eriksen E, Brixen K, Russo L, Claessens F, Papanastasiou P, Antunez O, Su G, Bucci-Rechtweg C, Hruska J, Incera E, Vanderschueren D, Orwoll E: Fracture risk and zoledronic acid therapy in men with osteoporosis. *N Engl J Med* 2012 367(18):1714-23
221. **Langdahl BL**, Harsløf T: Medical treatment of osteoporotic vertebral fractures. *Ther Adv Musculoskel Dis* 2011 3(1):17-29
222. Fahrleitner-Pammer A, **Langdahl B**, Marin F, Jakob F, Karras D, Barrett A, Ljunggren Ö, Walsh J, Rajzbaum G, Barker C, Lems W: Fracture rate and backpain during and after discontinuation of teriparatide: 36 month data from the European Forsteo Observational Study. *Osteoporos Int* 2011 22(19):2709-19
223. Harsløf T, Tofteng CL, Husted LB, Nyegaard M, Børglum A, Carstens M, Stenkjær L, Brixen K, Eiken P, Jensen JE, Mosekilde L, Rejnmark L, **Langdahl BL**: Polymorphisms of the peroxisome proliferators-activated receptor (PPAR) gene are associated with osteoporosis. *Osteoporos Int* 2011 22(10):2655-66
224. Harsløf T, Husted LB, Nyegaard M, Carstens M, Stenkjær L, Brixen K, Eiken P, Jensen JE, Børglum AD, Mosekilde L, Rejnmark L, **Langdahl BL**: Polymorphisms in the ALOX12 gene and osteoporosis. *Osteoporosis Int* 2011 22(8):2249-59

225. Eiken P, Hansen M, Kristensen B, **Langdahl BL**, Abrahamsen B: Osteoporosis and breast cancer. Diagnosis and treatment. *Ugeskr Laeger* 2011. 173(8):577-81
226. Harsløf T, Wamberg L, Møller L, Stødtkilde-Jørgensen H, Ringgaard S, Pedersen SB, **Langdahl BL**: Rosiglitazone decreases bone mass and bone marrow fat. *J Clin Endocrinol Metab* 2011 96(5):1541-8
227. Harsløf T, Husted LB, Carstens M, Stenkjær L, Sørensen L, Pedersen SB, **Langdahl BL**: The expression and regulation of bone-acting cytokines in human peripheral adipose tissue in organ culture. *Horm Metab Res* 2011 43(7):477-82
228. Vestergaard P, Mosekilde L, **Langdahl B**: Fracture prevention in postmenopausal women. *BMJ Clin Evid* 2011:1109
229. Rasmussen TA, Tolstrup M, Melchjorsen J, Frederiksen CA, Nielsen US, **Langdahl BL**, Østergaard L, Laursen AL: Evaluation of cardiovascular biomarkers in HIV-infected patients switching to abacavir or tenofovir based therapy. *BMC Infect Dis* 2011 11:267
230. Jakob F, Oertel H, **Langdahl B**, Ljunggren O, Barrett A, Karras D, Walsh JB, Farhleitner-Pammer A, Rajzbaum G, Barker C, Lems WF, Marin F: Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study. *Eur J Endocrinol* 2012 166(1):87-97
231. Eiken PA, **Langdahl BL**, Eiken FL, Walter S, Poulsen MH, Abrahamsen B: Prevention and treatment of osteoporosis during treatment of non-metastatic prostate cancer. *Ugeskr Laeger* 2011 173(48):3093-6
232. Recker RR, Ste-Marie LG, **Langdahl B**, Czerwinski E, Bonvoisin B, Masanauskaitė D, Rowell L, Felsenberg D. Effects of intermittent intravenous ibandronate injections on bone quality and micro-architecture in women with postmenopausal osteoporosis: The DIVA study *Bone* 2010 46(3):660-5
233. Büniger MH, Oxlund H, Hansen TK, Sørensen S, Bibby BM, Thomsen JS, **Langdahl BL**, Besenbacher F, Pedersen JS, Birkedal H: Stontium and bone nanostructure in normal and ovariectomised rats investigated by scanning small-angle X-ray scattering. *Calcif Tissue Int* 2010 86(4):294-306
234. Andersen T, Christensen FB, **Langdahl BL**, Ernst C, Fruensgaard S, Ostergaard J, Andersen JL, Rasmussen S, Niedermann B, Høy K, Helmig P, Holm R, Lindblad BE, Hansen ES, Egund N, Büniger C: Fusion mass bone quality after uninstrumented spinal fusion in older patients. *Eur Spine J* 2010 19(12):2200-08
235. Nielsen DS, **Langdahl BL**, Sørensen OH, Sørensen HA, Brixen KT: Persistence to medical treatment of osteoporosis in women at three different clinical settings – a historical cohort study. *Scand J Public Health* 2010 38(5):502-7
236. Harsløf T, Husted LB, Carstens M, Stenkjaer L, **Langdahl BL**: Genotypes and haplotypes of the estrogen receptor genes, but not the retinoblastoma-interacting zinc finger protein 1 gene are associated with osteoporosis. *Calcif Tissue Int* 2010 87(1):25-35
237. Gonzáles-Bofill N, Husted LB, Harsløf T, Tofteng CL, Abrahamsen B, Eiken P, Vestergaard P, **Langdahl BL**: Effects of COLIA1 polymorphisms and haplotypes on perimenopausal bone mass, postmenopausal bone loss and fracture risk. *Osteoporos Int* 2011 22(4):1145-56
238. Belsing TZ, Tofteng C, **Langdahl BL**, Charles P, Feldt-Rasmussen U: Can bone loss be reversed by antithyroid drug therapy in premenopausal women with Graves' disease? *Nutr Metab* 2010 7:72
239. Eriksen CG, Olsen H, Husted LB, Sørensen L, Carstens M, Søballe K, **Langdahl BL**: The expression of IL-6 by osteoblasts is increased in healthy elderly individuals. Stimulated proliferation and differentiation are unaffected by age. *Calcif Tissue Int* 2010 87(5):414-23
240. **Langdahl BL**: The genetics of response to estrogen treatment. *Clin Cases Miner Bone Metab* 2009 6(1):44-9
241. Husted LB, Harsløf T, Gonzalez-Bofill N, Schmitz A, Carstens M, Stenkjaer L, **Langdahl BL**: Haplotypes of promoter and intron 1 polymorphisms in the COLIA1 gene are associated with increased risk of osteoporosis. *Calcif Tissue Int* 2009 84(2):85-96
242. Recker RR, Ste-Marie LG, **Langdahl B**, Masanauskaitė D, Ethgen D, Delmas PD: Oral ibandronate preserves trabecular microarchitecture: micro-computed tomography findings from the oral ibandronate osteoporosis vertebral fracture trial in North America and Europe study. *J Clin Densitom* 2009 12(1):71-76
243. Nissen N, Madsen JS, Bladbjerg EM, Beck Jensen JE, Jørgensen NR, **Langdahl B**, Abrahamsen B, Brixen K: No association between hip geometry and four common polymorphisms associated with fracture: the Danish Osteoporosis Prevention Study. *Calcif Tissue Int* 2009 84(4):276-85
244. **Langdahl BL**, Marin F, Shane E, Dobnig H, Zanchetta JR, Maricic M, Krohn K, See K, Warner MR: Teriparatide versus Alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. *Osteoporosis Int* 2009 20(12):2095-104
245. **Langdahl BL**, Hitz M, Melsen B, Pinholt EM: [Jaw necrosis following treatment with bisphosphonates – the dose is of crucial significance for the risk]. *Ugeskr Laeger* 2009 171(13):1103

246. **Langdahl BL**, Rajzbaum G, Jakob F, Karras D, Ljunggren O, Lems WF, Fahrleitner-Pammer A, Bernard Walsh J, Barker C, Kutahov A, Marin F. Reduction in Fracture Rate and Back Pain and Increased Quality of Life in Postmenopausal Women Treated with Teriparatide: 18-Month Data from the European Forsteo Observational Study (EFOS) *Calcif Tissue Int* 2009 85(6):484-93
247. **Langdahl BL**, Uitterlinden AG, Ralston SH, Trikalinos TA, Balcells S, Brandi ML, Scollen S, Lips P, Lorenc R, Obermayer-Pietsch B, Reid DM, Armas JB, Arp PP, Bassiti A, Bustamante M, Husted LB, Carey AH, Pérez Cano R, Dobnig H, Dunning AM, Fahrleitner-Pammer A, Falchetti A, Karczmarewicz E, Kruk M, van Leeuwen JP, Masi L, van Meurs JB, Mangion J, McGuigan FE, Mellibovsky L, Mosekilde L, Nogués X, Pols HA, Reeve J, Renner W, Rivadeneira F, van Schoor NM, Ioannidis JP: Large-scale analysis of association between polymorphisms in the Transforming Growth Factor Beta 1 gene (TGFB1) and osteoporosis: The GENOMOS Study. *Bone* 2008 42(5):969-81
248. van Meurs J, Trikalinos TA, Ralston SH, Balcells S, Brandi ML, Brixen K, Kiel DP, **Langdahl BL**, Lips P, Ljunggren O, Lorenc R, Obermayer-Pietsch B, Ohlsson C, Pettersson U, Reid DM, Rousseau F, Scollen S, Van Hul W, Agueda L, Akesson K, Benevolenskaya LI, Ferrari SL, Hallmans G, Hofman A, Husted LB, Kruk M, Kaptoge S, Karasik D, Karlsson MK, Lorentzon M, Masi L, McGuigan FE, Mellström D, Mosekilde L, Nogués X, Pols HA, Reeve J, Renner W, Rivadeneira F, van Schoor NM, Weber K, Ioannidis JP, Uitterlinden AG: Large-scale analysis of association between polymorphisms in the LRP-5 and -6 genes and osteoporosis: The GENOMOS Study. *JAMA* 2008 299(11):1277-90
249. Rajzbaum G, Jakob F, Karras D, Ljunggren O, Lems WF, **Langdahl BL**, Fahrleitner-Pammer A, Walsh JB, Gibson A, Tynan AJ, Marin F: Characterization of patients in the European Forsteo Observational Study (EFOS): postmenopausal women entering teriparatide treatment in a community setting. *Curr Med Res Opin* 2008 24(2):377-84
250. **Langdahl BL**, Rejnmark L: Osteoporosis – New therapeutic possibilities. *Ugeskr Laeger* 2008 170(12):1043.
251. Mosekilde L, Vestergaard P, **Langdahl B**: Fracture prevention in postmenopausal women. *Am Fam Physician* 2008 77(10):1447-8.
252. Schultz M, Kistorp C, **Langdahl B**, Hildebrandt P, Faber J: N-Terminal-Pro-B-Type Natriuretic Peptide in acute Hyperthyroidism. *Thyroid* 2007 17(3):237-241
253. de Maat MP, Madsen JS, **Langdahl BL**, Bladbjerg EM, Tofteng CL, Abrahamsen B, Rejnmark L, Brixen K, Christensen K, Jespersen J, Kristensen SR: Genetic variation in estrogen receptor, C-reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. *Thromb Haemost.* 2007 97(2): 234-239
254. Vilariño-Güell C, Miles LJ, Duncan EL, Ralston SH, Compston JE, Cooper C, **Langdahl BL**, MacLelland A, Pols HA, Reid DM, Uitterlinden AG, Steer CD, Tobias JH, Wass JA, Brown MA: PTHR1 polymorphisms influence BMD variation through effects on the growing skeleton. *Calcif Tissue Int* 2007 81(4):270-8
255. Mosekilde L, **Langdahl BL**, Nielsen LR, Vestergaard P: The usefulness of calcium and vitamin D supplementation after the Women's Health Initiative trial. *Ugeskr Laeger.* 2007 169(39):3273-6
256. Mosekilde L, Vestergaard P and **Langdahl B**: Fracture prevention in postmenopausal women. *BMJ Clin Evid* 2007:1109
257. Reid DM, Mackay I, Wilkinson S, Miller C, Schuette DG, Compston J, Cooper C, Duncan E, Galwey N, Keen R, **Langdahl B**, McLellan A, Pols H, Uitterlinden A, O'Riordan J, Wass JAH, Ralston SH and Bennett ST: Cross-calibration of dual-energy X-ray densitometers for a large, multi-center genetic study of osteoporosis. *Osteop Int* 2006 17(1):125-32
258. Ralston SH, Uitterlinden AG, Brandi ML, Balcells S, **Langdahl BL**, Lips P, Lorenc R, Obermayer-Pietsch B, Scollen S, Bustamante M, Husted LB, **Carey AH**, Diez-Perez A, Dunning AM, Falchetti A, Karczmarewicz E, Kruk M, van Leeuwen JP, van Meurs JB, Mangion J, McGuigan FE, Mellibovsky L, del Monte F, Pols HA, Reeve J, Reid DM, Renner W, Rivadeneira F, van Schoor NM, Sherlock RE, Ioannidis JP: Large-scale evidence for the effect of the COL1A1 Sp1 polymorphism on osteoporosis outcome: The GENOMOS Study. *PLoS Med* 2006 3(4):e90
259. Uitterlinden AG, Ralston SH, Brandi ML, Balcells S, Carey AH **Langdahl BL**, Lips P, Lorenc R, Obermayer-Pietsch B, Reeve J, Reid DM, Amedei A, Bassiti A, Bustamante M, Husted LB, Diez-Perez A, Dobnig H, Dunning AM, Enjuanes A, Fahrleitner-Pammer A, Fang Y, Karczmarewicz E, Kruk M, van Leeuwen JP, Mavilia C, van Meurs JB, Mangion J, McGuigan FE, Pols HA, Renner W, Rivadeneira F, van Schoor NM, Scollen S, Sherlock RE, Ioannidis JP: The association between common vitamin D receptor gene variations and osteoporosis: a participant-level meta-analysis. *Ann Intern Med* 2006, 145(4):255-64
260. Büniger MH, Foss M, Erlacher K, Hougaard MB, Chevallier J, **Langdahl B**, Büniger C, Birkedal H, Besenbacher F, Pedersen JS: Nanostructure of the neurocentral growth plate: Insight from scanning small angle x-ray scattering, atomic force microscopy and scanning electron microscopy. *Bone* 2005 39(3):530-41

261. Ioannidis JP, Ng MY, Sham PC, Zintzaras E, Lewis CM, Deng HW, Econ MJ, Karasik D, Devoto M, Kammerer CM, Spector T, Andrew T, Cupples LA, Foroud T, Kiel DP, Koller D, **Langdahl B**, Mitchell BD, Peacock M, Recker R, Shen H, Sol-Church K, Spotila LD, Uitterlinden AG, Wilson SG, Kung AW, Ralston SH: Meta-analysis of genome wide scans provides evidence for gender and site specific regulation of bone mass. *J Bone Min Res* 2007 22(2):173-183
262. Mosekilde L, Vestergaard P and **Langdahl B**: Fracture prevention in postmenopausal women. *Clin Evid* 2006:1543-60
263. B nger MH, Foss M, Erlacher K, Li H, Zou X, **Langdahl B**, B nger C, Birkedal H, Besenbacher F, Pedersen JS: Bone nanostructure near titanium and porous tantalum implants studied by scanning small angle x-ray scattering. *Eur Cell Mater* 2006 12:81-91
264. Knudsen S, Harsl f T, Carstens M, Stenkj r L, **Langdahl BL**: Interleukin-1 alpha polymorphisms and the effect on BMD and the risk of vertebral fractures. *Calcif Tissue Int* 2006 80(1):21-30
265. Ralston SH, Bennett S, Cardon L, Compston J, Cooper C, Galwey N, Keen R, **Langdahl BL**, MacKay I, Pols H, Reid DM, Uitterlinden A and Wass J: Loci for regulation of bone mineral density in Caucasian men and women identified by a large whole-genome linkage scan: The FAMOS study. *Hum Mol Genet* 2005, 14(7):943-51
266. Abrahamsen B, Hjelmberg JV, Kostenuik P, Stilgren LS, Kyvik K, Adamu S, Brixen K, **Langdahl BL**. Circulating amounts of osteoprotegerin and RANK ligand: Genetic influence and relationship with BMD assessed in female twins. *Bone* 2005 36(4):727-35
267. **Langdahl BL**, Stenkjaer L, Carstens M, Tofteng CL, Eriksen EF. A CAG repeat polymorphism in the androgen receptor gene is associated with reduced bone mass and increased risk of osteoporotic fractures. *Calcif Tissue Int.* 2003 Sep;73(3):237-43
268. B nger MH, **Langdahl BL**, Andersen TB, Lind M, Eriksen EF and B nger CE: Semiquantitative mRNA measurements of osteoinductive growth factors in human iliac-crest bone: Expression of transcription factor LMP mRNA splice variants in human bone. *Calcif Tissue Int* 2003 73(5):446-454
269. **Langdahl BL**: Arv og osteoporose. *M nedsskr Prakt L gegern* 2002, 80: 325-334.
270. **Langdahl BL**, Carstens M, Stenkj r L, Eriksen EF: Polymorphisms in the osteoprotegerin gene are associated with osteoporotic fractures and reduced bone mass. *J Bone Miner Res* 2002 17(7):1245-1255
271. **Langdahl BL**, L kke E, Carstens M, Stenkj r LL, Eriksen EF. Osteoporotic fractures are associated with an 86-base pair repeat polymorphism in the interleukin-1 receptor antagonist but not with polymorphisms in the interleukin 1beta gene. *J Bone Miner Res* 2000 15(3):402-14
272. **Langdahl BL**, L kke E, Carstens M, Stenkj r L, Eriksen EF: A TA-repeat polymorphism in the estrogen receptor gene is associated with osteoporotic fractures but polymorphisms in the first exon and intron are not. *J Bone Miner Res* 2000 15(11):2222-30
273. **Langdahl BL**, Gravholt CH, Brixen K, Eriksen EF. Polymorphisms in the vitamin D receptor gene and bone mass, bone turnover and osteoporotic fractures. *Eur J Clin Invest* 1999 30(7):6078-17
274. Eriksen EF, **Langdahl B**, Rungby J, Kassem M. Hormone replacement therapy prevents osteoclastic hyperactivity: A histomorphometric study in early postmenopausal women. *J Bone Miner Res* 1999 14(7):1217-21
275. Kristensen K, **Langdahl BL**, Pedersen SB, Richelsen B. Serum-leptin levels in women and leptin production from human adipose subcutaneous biopsies is unaffected by thyroid hormones. *Metabolism* 1999 48(12):1603-1607
276. Kveiborg M, Kassem M, **Langdahl BL**, Eriksen EF, Clark BFC, Rattan SIS. Telomere shortening during aging of human osteoblasts in vitro and leukocytes in vivo: lack of excessive telomere loss in osteoporotic patients. *Mech Ageing Dev* 1999 106:261-71
277. Rix M, Andreassen H, Eskildsen P, **Langdahl B**, Olgaard K. Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. *Kidney Int* 1999 56(3):1084-93
278. S rensen TH, **Langdahl BL**, Eriksen EF, Charles P. F r m nd osteoporose? *M nedsskr Prakt l gegern* 1998 76:1213-21.
279. **Langdahl BL**, Kassem M, M ller MK, Eriksen EF. The effects of IGF-I and IGF-II on proliferation and differentiation of human osteoblasts and interactions with growth hormone. *Eur J Clin Invest* 1998 28(3):176-83
280. **Langdahl BL**, Eriksen EF. The influence of thyroid hormones on bone turnover in health and osteopetrosis. Invited commentary. *Eur J Endocrinol* 1998 139:10-1
281. **Langdahl BL**, Eriksen EF. Genetics in osteoporosis. In: Russel G, Skerry T, Kollenkirchen, editors. *Novel Approaches to Treatment of Osteoporosis*. Heidelberg: Springer Verlag; 1998. p. 83-101
282. Pociot F, Hansen PM, Karlsen AE, **Langdahl BL**, Johannesen J, Nerup J. TGF-b1 gene mutations in insulin-dependent diabetes mellitus and diabetic nephropathy. *J Am Soc Nephrol* 1998 9(12):2302-7
283. **Langdahl BL**, Ralston SH, Grant SFA, Eriksen EF. An Sp1 binding site polymorphism in the COL1A1 gene predicts bone density and osteoporotic fractures in both men and women. *J Bone Miner Res*

1998 13(9):1384-9

284. **Langdahl BL**, Knudsen JY, Jensen HK, Gregersen N, Eriksen EF. A sequence variation: 713-8delC in the transforming growth factor-b1 gene has higher prevalence in osteoporotic women than in normal women and is associated with very low bone mass in osteoporotic women and increased bone turnover in both osteoporotic and normal women. *Bone* 1997 20(3):289-94
285. Johansson AG, Eriksen EF, Lindh E, **Langdahl B**, Blum WF, Lindahl A, Ljunggren Ö, Ljunghall S. Reduced serum levels of the growth hormone-dependent IGF binding protein and a negative bone balance at the level of individual remodeling units idiopathic osteoporosis in men. *J Clin Endocrinol Metab* 1997 82(9):2795-8
286. **Langdahl BL**, Loft AGR, Møller N, Weeke J, Eriksen EF, Mosekilde L, Charles P. Is skeletal responsiveness to thyroid hormone altered in primary osteoporosis or following estrogen replacement therapy? *J Bone Miner Res* 1997 12(1):78-88
287. Eriksen EF, **Langdahl BL**. The pathogenesis of osteoporosis. *Horm Res* 1997;48(suppl.5):78-82
288. **Langdahl BL**, Mortensen L, Vesterby A, Eriksen EF, Charles P. Bone histomorphometry in hypoparathyroid patients treated with vitamin D. *Bone* 1996 18(2):103-8
289. **Langdahl BL**, Loft AG, Møller N, Weeke J, Eriksen EF, Mosekilde L, Charles P. Skeletal responsiveness to thyroid hormone is not altered at menopause. *Bone* 1996 19(5):557-64
290. **Langdahl BL**, Loft AGR, Eriksen EF, Mosekilde L, Charles P. Bone mass, bone turnover, calcium homeostasis, and body composition in surgically and radioiodine-treated former hyperthyroid patients. *Thyroid* 1996 6(3):169-75
291. **Langdahl BL**, Loft AGR, Eriksen EF, Mosekilde L, Charles P. Bone mass, bone turnover, body composition, and calcium homeostasis in former hyperthyroid patients treated by combined medical therapy. *Thyroid* 1996 6(3):161-8
292. **Langdahl BL**, Loft AGR, Eriksen EF, Mosekilde L, Charles P. Bone mass, bone turnover and body composition in former hypothyroid patients receiving replacement therapy. *Eur J Endocrinol* 1996 134:702-9
293. Eriksen EF, Kassem M, **Langdahl B**. Growth hormone, insulin-like growth factors and bone remodelling. *Eur J Clin Invest* 1996 26:525-34
294. Eriksen EF, Møller MK, **Langdahl B**. New and developing therapies in the prevention and treatment of osteoporosis. *European Menopause Journal* 1996 3(2 (suppl)):129-35
295. Eriksen EF, Kassem M, **Langdahl BL**. European and North American experience with HRT for the prevention of osteoporosis. *Bone* 1996 19(5 suppl):179-83
296. Eriksen EF, **Langdahl B**. Bone changes in metabolic bone disease. *Acta Orthop Scand* 1995 66(suppl 266):195-201
297. Eriksen EF, **Langdahl B**, Kassem M. The cellular basis of osteoporosis. In: Cooper C, Reeve J, editors. *SPINE: State of the art reviews*. Philadelphia: Hanley & Belfus, Inc.; 1994. p. 23-62.
298. Eriksen EF, **Langdahl B**. Bone remodeling and its consequences for bone structure. In: Odgaard A, Weinans H, editors. *Bone structure and remodeling*. Amsterdam: World Scientific; 1994. p. 25-36.